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Listeria monocytogenes is pathogenic intracellular foodborne bacterium that 
causes listeriosis, a rare, but serious disease in humans. Despite the use of antibiotics, 
the mortality rate remains at 20-30%.  The ability of L. monocytogenes to survive 
transmission through food systems and to cause disease is attributed in part to the 
regulatory networks that control environmental stress adaptation and virulence 
functions. Therefore, a comprehensive understanding of the factors that are important 
to virulence, stress response and antimicrobial resistance will help us better develop 
novel inhibitors for therapeutics. With the information garnered from select regulators, 
it is possible to identify new drug targets and new drugs for treatment alternatives.  
The purpose of this research in L. monocytogenes is to (i) determine the 
contributions of select transcriptional regulators to virulence functions, (ii) assess the 
contributions of two regulators to antimicrobial peptides response, and (iii) identify 
novel small molecule inhibitors of the regulator σB. In summary, we found that of 
central transcriptional regulators, σB, PrfA, HrcA, CtsR, σL, σH, and σC, σB contributes 
to invasion, PrfA contributes to cell-to-cell growth and CtsR, in addition to PrfA and 
σB, contributes to virulence in a guinea pig model of listeriosis.  We determined that 
σB and σL are important to controlling expression of genes needed for resistance to the 
select antimicrobial peptides SdpC and Nisin, thus indicating that σB has a role in 
  
virulence and stress survival as well as antimicrobial resistance. Therefore, we focused 
on σB as a promising novel drug target for the treatment of listeriosis. From a library 
of 57,000 small molecules, we identified a novel compound, sigmastatin, which 
inhibits the activity of σB and its regulon, inhibits Bacillus subtilis σB and severely 
impedes L. monocytogenes enterocyte invasion. With a solid understanding of the 
contributions and roles of various regulators in L. monocytogenes, novel inhibitors can 
be used to target those regulators, like σB, which are associated with survival, 
pathogenesis, and resistance. These novel agents can be used to treat listeriosis, 
extrapolated for use against other similar clinically relevant diseases, or used to gain 
insight into physiology of pathogenic bacteria and related gene regulation. 
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 CHAPTER 1 
INTRODUCTION 
 
Listeria monocytogenes and human listeriosis 
The foodborne pathogen L. monocytogenes is an environmentally ubiquitous 
organism that can easily contaminate processing environments and, thus, food systems 
(32). While the disease caused by L. monocytogenes, called listeriosis, is rare, it can be 
fatal for susceptible individuals. L. monocytogenes infection is typically associated  
with underlying conditions. Specifically, it poses a serious threat to vulnerable 
populations, including pregnant women and their fetuses, neonates, the elderly and 
those with impaired immune systems (13).  Among foodborne pathogens, it has one of 
the highest mortality rates (20%) and accounts for 10% of all foodborne deaths in the 
U.S. (29).  It is capable of breaching three critical barriers intended to protect a human 
from pathogens: the gastrointestinal barrier, the blood-brain barrier, and the 
fetoplacental barrier. As a result, it can cause gastroenteritis, septicemia, meningitis, 
encephalitis, and abortion or stillbirth of a fetus.  
Currently, antibiotics are employed for use against L. monocytogenes infection 
(42); however, because of the high case mortality rate caused by listeriosis, improved 
treatment is needed. Furthermore, various studies have identified single and multidrug 
resistant strains of L. monocytogenes isolated from foods and the environment (18). In 
one study, 10.9% of Listeria spp. and more specifically, 0.6% of L. monocytogenes 
isolated from retail foods displayed resistance to one or more antibiotics (46). In 
another study, 20 of 21 L. monocytogenes strains isolated from cabbage, 
environmental and water samples were resistant to two or more antibiotics (33).  This 
increasing incidence of multidrug resistant pathogens (17) elicits the concern for lack 
of antibiotic recourse against the pathogenic bacteria. Thus, attempts to better 
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characterize the factors that contribute to virulence and antimicrobial resistance in L. 
monocytogenes will help provide a comprehensive understanding of the potential 
various factors have as viable targets for chemotherapeutic development.  
Transcription factors 
Transcription factors promote differential expression of various genes 
depending upon the situational and temporal requirements of the bacterial cell (5). 
Pathogenic microorganisms require the ability to utilize a variety of proteins to adapt 
to stressful external conditions both inside and outside the host (47). One method to 
counter these rapidly changing environments involves employing a myriad of factors 
that control transcription in a complex multilayered network (2); these factors include 
alternative sigma factors as well as other activators (such as virulence regulators) 
and/or repressors (such as heat shock regulators) (21).  
Alternative sigma factors dissociably interact with core RNA polymerase 
(RNAP), recognize certain promoter sequences and direct transcription of target gene 
sets critical to combating stress (21), resisting antimicrobials (3, 31) and maintaining 
viability and sustaining infection in the host (11, 30, 36). L. monocytogenes, for 
example, is exposed to adverse conditions in the environment, in food systems, during 
transmission and in the mammalian host. Therefore, in addition to general house 
keeping sigma factor σA, L. monocytogenes utilizes 4 alternative sigma factors, σB, σC, 
σH and σL to survive exposure.  General stress response sigma factor σB in particular 
aids L. monocytogenes in withstanding external stressors including acidic pH 
encountered in the stomach (pH 2), bile salts in the duodenum, and elevated 
osmolarity throughout the intestinal tract (8, 14, 15, 35). In addition to conferring 
protection to adverse environmental elements, which can be a prerequisite to virulence 
(44), σB has also been shown to play a role in pathogenicity of L. monocytogenes.  σB 
is important to regulating the transcription of a number of virulence genes including 
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inlAB (encoding two genes critical to attachment and invasion (26, 27)), bsh (encoding 
bile salt hydrolase needed for gastrointestinal passage (10, 12)) and prfA (encoding 
PrfA, which is the global virulence gene regulator critical to infection (45)) through 
upstream σB-dependent promoters (25). By regulating genes such as these, σB 
contributes to the establishment of infection in mammals (7, 19, 43).  σB has also been 
shown to contribute to virulence in other gram positive human pathogens, including 
Bacillus anthracis (16) and Staphylococcus aureus (24, 28). While the other 
alternative sigma factors in L. monocytogenes are important for surviving select 
stresses, it is well established that σB has a prominent role in stress resistance and 
virulence, making it an excellent target of focus for developing and identifying novel 
anti-infective compounds.   
Targeting L. monocytogenes using chemical biology 
Utilizing high-throughput chemical biology platforms for pharmaceutical 
development, researchers have the ability to extend drug discovery to identify novel 
small-molecule therapeutics from millions of compounds (1). Small molecules are 
simple organic chemical compounds, typically of low molecular weight, which can 
have useful biological effects (39). They are vital to biological functioning of living 
organisms (e.g. small molecules can function as hormones or neurotransmitters) and 
can bind macromolecules such as DNA, RNA or proteins to alter their activity (37, 
40). Small molecules are frequently used for medicinal purposes (37) and have been 
for centuries (i.e. plant and fungal extracts). The first isolated natural small molecule 
was morphine, which was derived from an opium plant and subsequently sold for 
medicinal purposes by Heinrich Emanuel Merck (23). In addition to naturally 
occurring products made by living cells (9), chemists also create synthetic small 
molecules by combining chemical building blocks, such as ethanol or benzene (6). 
Using a combinatorial synthesis approach, chemists can realize vast combinations of 
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core functional groups to create complex and diverse small molecules (4). This 
process of synthesizing combinatorial libraries of diverse compounds is called 
diversity-oriented synthesis (DOS) (41). Many of these synthetic compounds are 
modeled after naturally-occurring bio-active small molecules (41) because natural 
compounds have proven to be very effective for use in treatment.  
With their ability to cause phenotypic changes and modulate cell functions 
(37), small molecules can be used as probes for understanding biological systems (40), 
which then aids in the development of potential therapeutic drugs. This field of study 
is called chemical biology or chemical genetics because it employs chemical 
compounds to study genetics. For example, in the same way classical geneticists 
create gene mutations to alter the function of a single-gene product, chemical 
biologists use exogenous small molecules to alter the function of a single-gene product 
(39). Both approaches provide a more complete understanding of the biological 
consequences within a cellular context. When small-molecule screens are performed 
in a high-throughput format, chemical biologists expand current knowledge about 
biological processes and phenotypic consequences to identify novel and medicinally-
hopeful perturbational agents (perturbagens) in a rapid and comprehensive manner. 
This approach can effectively be used to identify novel small molecules for targeting 
diseases caused by prokaryotes. The extensively studied intracellular pathogen, L. 
monocytogenes, is an ideal model for identifying small molecule agents for treating 
bacterial infections. By selecting specific biological targets in L. monocytogenes that 
are common to Gram-positive pathogens, knowledge garnered pertaining to drug 
discovery can be extrapolated for other bacteria. Also, attenuating the pathogen’s 
virulence and stress response attributes without killing it can eliminate selective 
pressure caused by disruption of essential gene functions (as done by classical 
antibiotics). Alleviating this pressure makes the pathogen susceptible to 
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pharmacological inhibitors ideally without eliciting resistance, reducing the likelihood 
of developing more bacteria impervious to the effects of antibiotics (34).  
Utilizing this approach, ground-breaking work performed by Hung et al. in 
Vibrio cholerae, demonstrated that small molecules can inhibit essential molecular 
processes required for transcription of virulence genes in V. cholerae (22, 38). Based 
on that research, we hypothesize that certain synthesized and/or naturally-derived 
small molecules targeting a specific biological factor, such as a transcription factor, 
will hinder the infective process of L. monocytogenes. A target of particular interest in 
L. monocytogenes is general stress response sigma factor B, σB.  As previously 
mentioned, it is an ideal target for inhibition by small molecules because it is 
important to both virulence and stress response and it is common to several significant 
human pathogens, such as those in the genera Bacillus and Staphyloccocus (44). 
Further impetus for targeting a factor, such as σB, which is specific to certain bacteria, 
is the aim of identifying well tolerated chemotherapy agents, which are not harmful to 
the mammalian host (20). 
Therefore, focusing our understanding on transcriptional regulators (and their 
interactions), which contribute to the regulation of stress survival, antimicrobial 
resistance and virulence gene repertoire of L. monocytogenes, will ultimately provide a 
solid information base, which we can use to develop novel inhibitors of factors critical 
to pathogenesis. This will improve the search for new efficacious anti-infective drug 
candidates against pathogenic organisms, such as L. monocytogenes and may boost 
our understanding of the finer aspects of gene-regulation. 
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 CHAPTER 2 
CONTRIBUTIONS OF MULTIPLE TRANSCRIPTIONAL REGULATORS TO 
LISTERIA MONOCYTOGENES VIRULENCE FUNCTIONS 
 
ABSTRACT 
The foodborne pathogenic bacterium, Listeria monocytogenes, causes listeriosis, a 
rare, but serious, invasive disease affecting both humans and animals.  The ability of 
L. monocytogenes to survive transmission through food systems and to cause disease 
is attributed to both its environmental stress survival capabilities and its virulence gene 
repertoire.  Stress response and virulence functions in L. monocytogenes have been 
ascribed to the pleiotropic transcriptional regulators σB and PrfA, however, little is 
known about the involvement of other transcriptional regulators in pathogenicity.  To 
assess contributions of various regulatory proteins to virulence and virulence-
associated phenotypes, L. monocytogenes laboratory parent strain 10403S and a 
collection of otherwise isogenic strains each bearing in-frame deletions in genes 
encoding alternative sigma factors σL, σH, or σC or repressors CtsR or HrcA were 
tested in: (i) invasion assays with Caco-2 intestinal epithelial cells; (ii) intracellular 
growth assays in J774 mouse macrophage-like cells; and (iii) intragastric infections in 
the guinea pig model.  We found that σB was essential for optimal invasion efficiency 
in intestinal epithelial cells and only PrfA was obligatory for wildtype cytosolic 
growth and spread.  In addition to PrfA and σB, we found that CtsR also contributes to 
virulence during intragastric infection in the guinea pig. In summary, while no clear 
virulence-associated phenotypes were attributed to L. monocytogenes σL, σH, σC, or 
HrcA under the conditions tested, it is possible that regulatory networks exist among 
these regulators to enable at least partial functional compensation in the absence of a 
given factor.  
             12
  
INTRODUCTION 
Rapid adaptation to stress and the external environment affords the 
intracellular pathogen Listeria monocytogenes the ability to survive and persist in 
various niches, including mammalian hosts (6, 9). As a result L. monocytogenes 
causes a severe invasive disease, listeriosis, with a 20-30% fatality rate in the US (22). 
A network of regulatory proteins, such as alternative sigma factors (σB, σL, σH, σC), 
two-component regulators, and other transcriptional activators or repressors (i.e. PrfA, 
CtsR, HrcA), guides RNA polymerase to recognize certain promoter sequences. 
Utilization of this network permits coordination of signals and elicits responses by 
promoting differential expression of specific genes. The complex concerted effort of 
these regulatory proteins allows L. monocytogenes to sense and respond with 
specificity and fine tuning that allows survival and infection. Therefore, investigation 
into mechanisms through which L. monocytogenes controls virulence may provide 
insight and guidance for development of more effective disease intervention strategies.  
 Virulence roles for the global virulence regulator PrfA and the general stress 
sigma factor σB have been characterized and data indicate that PrfA and σB work in 
concert to coordinate the infectious process (3, 25, 31, 32). Virulence roles for others 
transcription factors, including alternative sigma factors σL, σH, σC and class I and III 
stress response repressors HrcA and CtsR, respectively, have been less extensively 
studied.  While σL has been shown to contribute to carbohydrate metabolism and 
antimicrobial resistance (1, 26, 29), σH is important for growth in minimal or alkaline 
media (28) and σC, a L. monocytogenes lineage II-specific extracytoplasmic function 
(ECF) sigma factor, is important for response to heat stress (33). Currently, these 
alternative sigma factors have not been indicated in virulence regulation. However, 
CtsR and HrcA, which negatively regulate genes important for survival of stress, 
including heat shock (12, 23, 24), control genes upregulated in vivo and encode 
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proteins relevant to virulence (3), such as proteases and chaperonins. The repressor 
CtsR, regulates virulence-associated Clp proteases. Under stress conditions, CtsR 
repression is relieved and Clp proteases degrade damaged proteins, allowing the cell to 
tolerate stress (4) and promote escape from phagosomes (30). Furthermore, HrcA 
binds operators and represses transcription of genes encoding chaperonins, such as 
DnaK, which is up regulated intracellularly in macrophages (12) and GroE, which 
helps the bacterium survive phagocytosis (8) and the vacuolar compartment (4). 
Moreover, transcriptomic analysis of CtsR and HrcA in the L. monocytogenes strain 
10403S (2), showed that CtsR and HrcA regulate genes encoding proteins important to 
acid and metabolic stress as well as virulence (14). Many of these genes are co-
regulated by σB, including hrcA itself (13) suggesting multiple layers of regulatory 
control amongst these regulatory proteins. 
To build a more comprehensive understanding of the role each regulator plays 
in virulence-associated functions, we performed in vitro assays, using single and 
double in-frame deletions of the regulators. We know that σB is essential for 
attachment and infection of enterocytes (in Caco-2 human intestinal epithelial cells 
(17)) and that PrfA is important for L. monocytogenes replication in macrophages (7). 
It was also shown that, in addition to PrfA, σB is required for a successful L. 
monocytogenes gastrointestinal infection in guinea pigs (11). Therefore, with this 
knowledge we evaluated σB, σL, σH, σC, CtsR, HrcA and PrfA to pinpoint and/or 
reaffirm the contributions of each protein to invasion, intracellular growth, and in vivo 
infection. We also began assessing the interactions between select regulators. 
Phenotypic characterization of the regulators during critical aspects of the infectious 
cycle provides a foundation for understanding the contributions of each protein in 
addition to working towards unraveling and understanding the complex transcriptional 
regulatory networks coordinated by these proteins.  
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MATERIALS AND METHODS 
Bacterial strains  
L. monocytogenes 10403S and eleven single and double isogenic mutant 
strains, ∆sigB(31), ∆sigC (Chaturongakul, unpub.), ∆sigH (Chaturongakul, unpub.), 
∆sigL(26), ∆ctsR (14), ∆hrcA (13), ∆prfA (32), ∆sigB/∆sigH (Chaturongakul, unpub.), 
∆sigB/∆ctsR (14), ∆ctsR/∆hrcA (13), and ∆sigB/∆hrcA (13) previously created in L. 
monocytogenes 10403S using splicing-by-overlap extension (SOE) PCR and allelic 
exchange mutagenesis used in this study (Table 2.1). Select single mutants including 
∆sigC, ∆sigH, ∆sigL, ∆ctsR, ∆hrcA were also assessed in the animal model. Strains 
were grown to stationary phase, i.e., OD600=0.8 +1hr, allowing comparison to previous 
assessments of regulators sigB and PrfA using cells grown to stationary phase (11). 
Invasion assay  
The human colorectal adenocarcinoma epithelial cell line Caco-2 (ATCC 
HTB-37) was cultured and invasion assays were performed as described by Garner et 
al. 2006 (11) with minor modifications. Briefly, 5.0 x 104 Caco-2 cells were seeded 
into 24-well plates (Costar, Corning, NY) 48 h prior to infection. For infection, the 
Caco-2 cells were inoculated with approximately 2.0x 107 L. monocytogenes cells 
(grown to stationary phase, i.e., OD600=0.8 +1hr); exact L. monocytogenes numbers 
used for infection were determined by plating on BHI agar.  Intracellular L. 
monocytogenes numbers were determined 90 min post infection as previously 
described (11).  Invasion efficiency was calculated as the number of bacteria 
recovered relative the number of bacteria used for inoculation (i.e., log (CFU/ml 
recovered/ CFU/ml inoculated). Data represent 4 independent experiments. Data were 
analyzed using one-way analysis of variance (ANOVA) and Dunnett’s t-test, 
performed in SAS® 9.0 (SAS Institute). Averages for three of four replicates for 
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Table 2.1:  Strains used in this study 
Strain Genotype Reference  
L. monocytogenes FSL X1-001 parent strain 10403S Bishop and Hinrichs, 1987 (2) 
L. monocytogenes FSL A1-254 10403S ∆sigB Wiedmann et al., 1998 (31) 
L. monocytogenes FSL C3-126 10403S ΔsigH Chaturongakul, unpublished 
L. monocytogenes FSL B2-124 10403S ∆sigL Chaturongakul, unpublished 
L. monocytogenes FSL C3-113 10403S ∆sigC Chaturongakul, unpublished 
L. monocytogenes FSL B2-046 10403S ∆prfA Wong et al., 2004 (32) 
L. monocytogenes FSL H6-190 10403S ∆ctsR Hu et al., 2007 (14) 
L. monocytogenes FSL B2-101 10403S ∆hrcA Hu et al., 2007 (13) 
L. monocytogenes FSL C3-123 10403S ∆sigB/∆sigH Chaturongakul, unpublished 
L. monocytogenes FSL H6-193 10403S ∆sigB/∆ctsR Hu et al., 2007 (14) 
L. monocytogenes FSL H6-194 10403S ∆sigB/∆hrcA Hu et al., 2007 (13) 
L. monocytogenes FSL H6-198 10403S ∆ctsR/∆hrcA Hu et al., 2007 (13) 
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 10403S, ∆sigB, ∆ctsR, ∆brcA, ∆sigB/∆ctsR, ∆sigB/∆hrcA, ∆ctsR/∆hrcA were 
represented previously (13). To determine if there were statistically significant 
interaction effects between the sigB and the sigH,  sigB and the ctsR, sigB and the 
hrcA, and the ctsR and the hrcA deletions, a two-way ANOVA (with Dunnett’s t-test) 
was performed.  Interaction is a term in a statistics model in which the effect of one 
variable on an outcome is a function of another variable. In our model, the dependent 
variable was invasion efficiency; the independent variables included sigB + sigH + 
sigB*sigH + replicate. The factors “sigB” and “sigH” in the model, for example, 
indicate the presence or absence of that gene in the strains tested.  This model was 
used to similarly assess the contributions of both genes in the other double mutant 
strains. 
Intracellular growth assay  
The mouse macrophage-like cell line J774A.1 (ATCC TIB-67) was cultivated 
at 37°C with 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) with Earle's 
salts and 1% Sodium Pyruvate (Gibco; Gaithersburg, MD) containing 10% fetal 
bovine serum (Gibco), 1.5 g/L Sodium Bicarbonate (Gibco), and 100µg/ml each 
Penicillin G and Streptomycin (J774 medium). At approximately 48 h before 
intracellular growth assays, J774 cells were seeded at a density of 2x105 cells/ml in 
each well of a 24 well plate using J774 medium without antibiotics. In order to 
activate macrophages, J774 cells were shifted to J774 media without antibiotics 
containing lipopolysaccharide (LPS; Sigma, St. Louis, MO) at final concentration of 
100ng/ml 24 hours before infection. At 30 min prior to assay, fresh media without 
antibiotics was added. J774 cells were then inoculated with L. monocytogenes at a 
multiplicity of infection (MOI) of 1. L. monocytogenes used for infection were grown 
to early stationary phase (defined as OD600=0.8 +1hr) in BHI, flash frozen and stored 
in liquid nitrogen before the assays; bacterial numbers were determined (on BHI agar 
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plates) after freezing and immediately prior to the assays. At 30 min post inoculation, 
the J774 cells were washed with 1ml sterile PBS, followed by addition of 1ml of fresh 
media with 50µg/ml gentamicin.  At 1.5, 3.5, 5.5, and 7.5 hr post-inoculation, 
inoculated J774 cells in different wells were washed three times with 1ml of sterile 
PBS and lysed with 500ul of ice cold sterile distilled water, followed by plating of the 
cell suspension on BHI agar to determine intracellular bacterial numbers at each time 
point. Intracellular growth was calculated as the number of bacteria recovered at each 
time point relative to the number of bacteria recovered at t=1.5 (i.e., [log CFU/ml t=x] 
- [log CFU/ml t=1.5]. Data represent 5 independent experiments. Data were analyzed 
using one-way ANOVA and Tukey’s studentized range (HSD) test, performed in 
SAS® 9.0 (SAS Institute). 
Animal care and housing condition  
Animal protocols (# 2002-0060) were approved by the Institutional Animal 
Care and Use Committee prior to initiation of the experiments. Male Hartley guinea 
pigs (Elm Hill, Chelmsford, MA) weighing approximately 300g at about 3 weeks of 
age were housed individually allowing for collection of each animal’s fecal material. 
Animals were provided with feed and water ad libitum. Cages were changed daily, and 
animal health and weight were monitored and recorded daily. Animals were 
acclimated for 5 days prior to infection.  
Intragastric infection of guinea pigs  
Intragastric infections of guinea pigs were performed as described previously 
(11). Briefly, animals were anesthetized with isoflurane administered via inhalation 
and L. monocytogenes (1 x1010 CFU) was inoculated intragastrically after stomach pH 
was buffered using by administrating 1.5 ml of PBS containing 125 mg calcium 
carbonate (pH 7.4). Data represent 4 independent experiments. 
Enumeration of L. monocytogenes from organs   
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Animals were euthanized for organ harvest at 72 h p.i. as was previously 
established by (20). The liver, mesenteric lymph nodes (MLN) and small intestine (a 
20-cm portion, immediately proximal to the cecum) were aseptically removed, and 
processed according to Garner et al. 2006. Additionally, to confirm L. monocytogenes 
presence for each organ, 10ml of homogenate was added to 90ml of Listeria 
Enrichment Broth (Becton Dickenson, Sparks, MD) and incubated at 30°C for 48hrs, 
after which it was streaked onto Oxford agar (Oxoid, Ogdensburg, NY). After 
incubation at 30°C for 48 h, colonies exhibiting Listeria-like morphology were 
recorded as L. monocytogenes.   
Enumeration of L. monocytogenes from feces 
Fecal pellets from each animal were collected daily and enumerated according 
to Garner et al., 2006. After incubation at 30°C for 48 h, colonies exhibiting Listeria-
like morphology were counted and recorded as L. monocytogenes. L. monocytogenes 
identification was confirmed on a representative subset of these colonies by plating on 
LMPM agar (Biosynth Biochemica & Synthetica, Naperville, Ill.). 
Statistical analyses  
Data were analyzed using general linear model (GLM) with Tukey’s 
studentized range (HSD) test or Dunnett’s t-test. Analysis was performed with 
Statistical Analysis Software (SAS) 9.0 (SAS Institute, Inc., Cary, NC).  
Histopathology and immunohistochemistry  
Histopathology and immunohistochemistry was performed by Brad Njaa and 
interpreted by Brad Njaa and Rachel Peters. Tissues from euthanized guinea pigs were 
fixed in 10% buffered formalin for a minimum of 48 h. Fixed tissues were processed 
using a Tissue Tek VIP E 300 (Sakura Finetek U.S.A., Inc. Torrance, CA) in 
preparation for paraffin embedding in a Tissue Tek embedding station (Sakura Finetek 
U.S.A., Inc.). Formalin-fixed, paraffin-embedded tissues were sectioned at a thickness 
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of 6 um, placed on glass slides, and stained with hematoxylin and eosin for 
microscopic evaluation. L. monocytogenes immunohistochemistry was performed as 
previously described (15) with minor modifications, as follows. Briefly, formalin-
fixed, paraffin-embedded tissues were sectioned to a thickness of 6 um and deposited 
on Probe-On glass slides. For each organ section investigated, one slide was stained 
using a polyclonal antibody to L. monocytogenes (Becton Dickinson, Sparks, MD), 
while the second slide was stained with a nonspecific antibody. The secondary 
antibody was an anti-immunoglobulin G antibody. All slides were stained using the 
avidin-biotin system, and the chromogen was diaminobenzidine. All slides were 
examined using an Olympus BX41 microscope. Photomicrographs were taken using a 
Q Imaging micropublisher 5.0 RTV (Burnaby, British Columbia, Canada) and a 50x 
or 100x oil objective lens. 
 
RESULTS 
Caco-2 intestinal epithelial cell assay demonstrates the requirement of σB for L. 
monocytogenes attachment and invasion.  
To assess the invasion capacity of various transcriptional regulator mutants in 
Caco-2 human enterocytes, we used laboratory parent strain 10403S and isogenic 
single mutants of regulators σB, σL, σH, σC, CtsR, HrcA and PrfA, as well as, strains 
containing double deletions of select regulators of interest, such as ∆sigB/∆sigH, 
∆sigB/∆ctsR, ∆sigB/∆hrcA, and ∆ctsR/∆hrcA (Figure 2.1). We found that in line with 
previous assessments (10, 17), the ∆sigB strain showed significantly reduced invasion 
capacity (p<0.05). Two double mutant strains, ∆sigB/∆ctsR and ∆sigB/∆hrcA showed 
significantly lower invasion than 10403S (p<0.05).  The ∆sigB/∆hrcA strain invasion 
capacity was similar to that of the single sigB knockout strain.  Two-way ANOVA 
analyses of invasion data showed no significant “SigB*HrcA” interaction effect on 
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Figure 2.1: Invasion efficiency of L. monocytogenes transcriptional regulator 
mutant strains in the intestinal epithelial cell line Caco-2. Data shown represent 
the average of four independent experiments. “*” indicates mutant was 
significantly different (p<0.05) than the 10403S parent strain (GLM, Dunnett). 
Two-way ANOVA showed no interaction effect for double mutants. Portions of 
this data have been published previously (13), see materials and methods. 
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 invasiveness (p>0.05). The ∆sigB/∆ctsR strain showed >0.5 log lower invasion than 
the ∆sigB strain. Initial analysis based on partial set of the data indicated an interaction 
of σB and CtsR on invasion (13), however, further analysis of complete set of data 
using two-way ANOVA analyses of “SigB*CtsR” indicated no significant interaction 
of σB and CtsR on invasion. This could mean that the lower invasion of ∆sigB/∆ctsR 
(lower than either of the respective single mutants) is probably a result of additive 
(rather than multiplicative) contributions of σB and CtsR to invasiveness. Though 
neither the ∆ctsR strain nor the ∆hrcA strain exhibited reduced invasiveness, the 
∆ctsR/∆hrcA strain exhibited lower invasion than either of the single mutants, 
suggesting that the loss of both proteins produces a compounding effect on invasion 
capacity. However, statistical analyses of invasion data showed no significant 
“CtsR*HrcA” statistical interaction effect on invasiveness (p>0.05). The ∆sigH strain 
exhibited higher invasion than its parent (though not statistically significant). 
Interestingly, the effect of deleting sigH in the ∆sigB/∆sigH strain appeared to have 
moderated the effect on invasion produced by loss of intact sigB gene. Specifically, 
the ∆sigB/∆sigH strain did not exhibit reduced invasion like all other strains with a 
∆sigB background (Figure 2.1). The statistical interaction effect of “SigB*SigH” was 
not significant, though (p>0.05).  
 
Intracellular growth assay indicates none of the selected regulators, other than 
PrfA, contribute to intracellular growth and spread.  
As L. monocytogenes is a facultative intracellular pathogen, we investigated a 
potential role for the transcriptional regulators in replication and spread in the 
intracellular microenvironment. In order to determine if the transcriptional regulator 
mutants were inhibited in their ability to adapt and grow once the bacteria were 
cytosolic, we performed intracellular growth assays using LPS-activated J774 mouse 
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 macrophage-like cells. The number of bacteria recovered at t=3.5, 5.5 and 7.5 hours 
post-infection (p.i.) were normalized to their respective number of bacteria recovered 
at initial invasion (t=1.5 h p.i.), in order to assess growth after and separate from 
invasion. This assay showed that σB does not directly contribute to intracellular growth 
in the macrophage, as its respective mutant and double mutants showed no inability to 
grow as compared to its parent strain. Likewise, σL, σH, σC, CtsR, and HrcA also did 
not contribute to intracellular growth, as their respective deletion mutants exhibited no 
hindrance of growth within the macrophages (Table 2.2). As seen previously (7), 
however, ∆prfA showed a complete loss in ability to multiply inside the cell (p<0.05; 
Table 2.2).  
Guinea pig model of listeriosis indicates CtsR contributes to L. monocytogenes 
virulence. 
  We used a guinea pig model of listeriosis to evaluate in vivo contributions of 
transcriptional regulators to virulence. It was previously discovered in our laboratory, 
that ∆prfA strain is avirulent and ∆sigB is virulence attenuated, thus they are both 
required for a successful L. monocytogenes gastrointestinal infection in guinea pigs 
(11). In order to gain a more comprehensive understanding of the roles of the other 
transcriptional regulators (σL, σH, σC, CtsR and HrcA) in comparison to PrfA and σB to 
virulence in vivo, we infected each guinea pig separately with 1x1010 CFU of each L. 
monocytogenes mutant in our panel of transcriptional regulators. Interestingly, we 
found that ∆ctsR was significantly less virulent than 10403S, as the animal infected 
with ∆ctsR had the lowest recovery (in log CFU/g organ) of L. monocytogenes in 
samples taken from the liver, spleen, mesenteric lymph nodes and the distal section of 
the ileum (p<0.05; Figure 2.2).  ∆ctsR was recovered from all tissues ~ 1 to 1.5 Log 
CFU/g less than 10403S. The relative contributions of the other transcriptional 
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(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 2.2: Recovery of L. monocytogenes strains from organs of infected 
guinea pigs. Data shown represent the average of 4 independent experiments. 
“*” indicates that recovery of a mutant was significantly different (p<0.05) 
from 10403S (GLM, Tukey HSD). MLN indicates mesenteric lymph node.
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Figure 2.3: Weight development for guinea pigs infected with various L. 
monocytogenes regulator mutants over 72 hours post-infection. Data shown 
represent the average of four independent experiments. Data were analyzed 
using general linear model (GLM) with Dunnett’s t-test.  
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(a) 
 
(b) 
 
(c) 
 
Figure 2.4: Recovery of L. monocytogenes strains from fecal specimens 
eliminated from infected guinea pigs. Data shown represent the average of 
four independent experiments. “*” indicates that recovery of a mutant was 
significantly different (p<0.05) than that of 10403S (GLM, Dunnett). 
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 regulators were negligible as their respective mutants showed no detectable 
differences or attenuation in virulence as compared to 10403S. According to 
histopathology, differences in tissue samples were minimal among guinea pigs 
infected with the various strains. The infection proceeded over 72 hours, during which 
the animal infected with ∆ctsR exhibited no physiological signs of distress, whereas 
the other animals demonstrated some anorexia. In fact, as compared to 10403S, the 
animals infected with ∆ctsR strain had the greatest positive % weight change, 
approximately 16% higher than 10403S at 72 hrs post-infection (p<0.05; Figure 2.3), 
similar to the uninfected control. This ∆ctsR-infected animals’ average weight change 
was similar to that of ∆sigB-infected animals in Garner et al.(11). Animals infected 
with the ∆ctsR strain also eliminated the least bacteria in their fecal matter, 
approximately 4 Log CFU/g less than animals infected with 10403S at both 48 and 72 
hours post-infection (p<0.05; Figure 2.4). Both animals infected with ∆sigL and ∆sigC 
eliminated significantly less bacteria than 10403S at 48 hours post-infection (p<0.05), 
however, not at any other time point.  
 
DISCUSSION 
A bacterium’s cellular adaptation to external conditions is largely dependent 
on differential expression of genes through the activity of multiple regulatory proteins 
including transcription factors. These complex and dynamic interactions between 
various regulatory proteins are critical to stress response (5) and the establishment of 
infection in a mammalian host for the intracellular pathogen L. monocytogenes (3, 25). 
Using phenotypic analysis to assess the contributions of seven transcriptional 
regulators, we determined whether and at what point each protein aids in the 
coordinated regulation of virulence and virulence-associated functions. Overall our 
data show that PrfA and σB are important to intracellular growth and entry, 
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respectively (3, 25), and that CtsR is an emerging factor that also promotes a 
successful infection in vivo. Simultaneously, we found that the other regulators 
examined (σL, σH, σC, and HrcA) do not seem to have apparent roles in virulence 
based on the conditions assessed here.  
Using an in vitro model of interaction between L. monocytogenes and intestinal 
cells, we observed that σB is indeed necessary for optimal invasion efficiency, as there 
was an appreciable loss in invasion capacity of ∆sigB as compared to its isogenic 
parent. This is consistent with its known role regulating inlA and inlB (27), thereby 
mediating attachment and early invasion in intestinal epithelium and was previously 
seen (17, 18). Also in agreement with previous work (18), ∆prfA grown to early 
stationary phase at 37ºC, showed no significant impediment in ability to invade as 
compared to its parent strain, further exemplifying its relatively dispensable role in 
invasion. We did see that in a ∆sigB/∆sigH, the loss of σH moderates the lowered 
invasion capacity as a consequence of the loss of σB, resulting in no reduction in 
invasion. This may simply indicate that σH selectively regulates genes to reduce 
invasiveness and σB regulation increases invasiveness. Similar interplay has been seen 
between PrfA and σB, in which σB moderates the effects of PrfA activity conferring to 
the cell better control during infection (25). Previous transcriptional profiling 
assessments indicate σB and negative transcriptional regulators CtsR and HrcA share 
overlapping transcriptomes (13, 14). This commingling of gene regulation indicates 
these proteins interact in a coordinated fashion to promote stress survival (13) and 
possibly virulence. Most notably, while the single mutant of the gene encoding the 
repressor CtsR did not exhibit loss of invasion capacity, we found that the 
∆sigB/∆ctsR strain exhibited invasion efficiency lower than a ∆sigB strain, consistent 
with previous reports (13, 14). This may indicate that regulator redundancy between 
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σB and CtsR causes an increased impairment in invasion; functional redundancy has 
been observed among alternative sigma factors in Bacillus subtilis (21). 
After examining the roles of the transcriptional regulators in replication and 
cell-to-cell spread, we found that only PrfA has an evident role in this aspect of L. 
monocytogenes pathogenesis. We surmise that under these conditions in the chosen 
cell line, the transcriptional regulators are not involved in intracellular growth during 
the infection process and are likely more important to a niche outside the host. 
Alternatively, they may be able to compensate for one another such that defects could 
not be detected in this assay.  
It has been shown that the guinea pig model of intragastric infection is the 
most representative of human listeriosis as transmitted through the ingestion of 
contaminated foods (11). The guinea pig was chosen for our in vivo assessments as it 
is a naturally permissive host for L. monocytogenes infection via the gastrointestinal 
route (19). While ∆prfA is avirulent and ∆sigB is virulence attenuated indicating both 
PrfA and σB are required for full scale infection in a guinea pig (11), our in vivo assay 
showed that CtsR is also important for L. monocytogenes pathogenesis. This correlates 
with known functions of CtsR. Surprisingly despite indications that, like CtsR, HrcA 
regulates genes important to virulence (dnaK, groESL) (4, 12), the ∆hrcA strain 
showed no attenuation of virulence in the guinea pig model.   
CtsR, encoded by lmo0229, modulates virulence associated Clp proteases that 
degrade misfolded proteins. Under stress conditions, CtsR repression is relieved and 
Clp proteases degrade damaged proteins, allowing the cell to tolerate stress. This 
ability is particularly important in escaping the phagolysosome and intracytoplasmic 
compartments (4, 30). Specifically, a ∆ctsR in EGD-e background was impaired in 
intracellular growth in P388D1 murine macrophage cell line as well as plaque 
formation, according to Chatterjee et al.,(4).  Though CtsR was not detected as a 
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requirement for virulence-associated functions in our in vitro experiments, it is clearly 
important in other models.  In light of this, it could be that our chosen cell culture 
experiments were limited in their detection of CtsR as an important regulator in 
virulence. It is also possible that CtsR may not be as important in in vitro cell culture 
models in the strain 10403S as it is in EGD-e because of heterogeneity of function 
across different strains. It may also be that our animal model better represented the 
true role of CtsR as compared to our tissue culture model.  Interestingly, the ctsR gene 
itself has been shown to be moderately up regulated specifically in the vacuolar 
compartment of the cell (4). Furthermore, of the 42 genes repressed by CtsR (14), 15 
are upregulated during infection in the mouse spleen (3). In line with this, a strain with 
inactive CtsR, whose repressor function is lost due to a single amino acid deletion, 
exhibits virulence attenuation in a mouse (16). It is possible that the ctsR mutant tested 
in the guinea pig could not escape vacuolar compartments to the cytoplasm to replicate 
and continue the intracellular life cycle in the animal model.  Because of the 
attenuation of the ∆ctsR strain seen in our studies, these data point to the necessity of 
the negative regulator CtsR in establishing a full-scale persistent L. monocytogenes 
infection in a mammal.  
CtsR is likely an important determinant in L. monocytogenes pathogenesis 
because it confers ability to adapt to stresses during transit through the intestinal tract 
(14), to overcome metabolic and nutritional limitations (14) and to withstand cytosolic 
and vacuolar stresses encountered in host cells (4, 30). While the other transcription 
factors did not play a demonstrable role in virulence and virulence-associated 
functions, it remains to be seen whether they play role indirect roles in virulence under 
other circumstances, such as infection of the brain or placenta. The observed 
phenotype may also be a result of overlapping regulation with other factors.  The 
evolutionary necessity for a compensatory mechanism to respond and neutralize any 
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deleterious effects resulting from the loss of certain factors is a possible explanation 
for lack of phenotype. While some factors such as PrfA, σB, and CtsR have roles in 
pathogenesis, it is plausible that the effects of the remaining regulators may be masked 
by the complex circuitry of the transcriptional regulators as a whole. The ability of L. 
monocytogenes to utilize this sophisticated network of factors advantageously permits 
this bacterium to swiftly modulate cell responses under a variety of adverse 
circumstances allowing the organism to sense, respond and survive.  
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 CHAPTER 3 
σB AND σL CONTRIBUTE TO L. MONOCYTOGENES 10403S RESPONSE TO 
THE ANTIMICROBIAL PEPTIDES SDPC AND NISIN1
 
 
ABSTRACT 
The ability of the foodborne pathogen Listeria monocytogenes to survive antimicrobial 
treatments is a public health concern, therefore, this study was designed to investigate 
genetic mechanisms contributing to antimicrobial response in L. monocytogenes.  In 
previous studies, the putative bacteriocin immunity gene lmo2570 was predicted to be 
regulated by the stress responsive alternative sigma factor, σB.  As the alternative 
sigma factor σL controls expression of genes important for resistance to some 
antimicrobial peptides, we hypothesized roles for lmo2570, σB, and σL in L. 
monocytogenes antimicrobial response.  Results from phenotypic characterization of a 
L. monocytogenes lmo2570 null mutant suggested that this gene does not contribute to 
resistance to nisin or to SdpC, an antimicrobial peptide produced by some strains of 
Bacillus subtilis.  While lmo2570 transcript levels were confirmed to be σB-dependent, 
they were σL-independent and were not affected by the presence of nisin under the 
conditions used in this study.  In spot-on-lawn assays with the SdpC-producing B. 
subtilis EG351, the L. monocytogenes ΔsigB, ΔsigL and ΔsigB/ΔsigL strains all 
showed increased sensitivity to SdpC, indicating that both σB and σL regulate genes 
contributing to SdpC resistance.  Nisin survival assays showed that σB and σL both 
affect L. monocytogenes sensitivity to nisin in broth survival assays, i.e., a sigB null 
mutant is more resistant than the parent strain to nisin, while a sigB null mutation in 
∆sigL background leads to reduced nisin resistance.  In summary, while the σB-
                                                 
1 Published as Palmer, M. E., M. Wiedmann, and K. J. Boor. 2009. σB and σL contribute to Listeria 
monocytogenes 10403S response to the antimicrobial peptides SdpC and nisin. Foodborne Pathog Dis 
6:1057-1065. 
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dependent lmo2570 does not contribute to resistance of L. monocytogenes to nisin or 
SdpC, both σB and σL contribute to the L. monocytogenes antimicrobial response. 
 
INTRODUCTION 
The Gram-positive, facultative intracellular foodborne pathogen Listeria 
monocytogenes is the causative agent of listeriosis, which has a human case-fatality 
rate > 20% in the U.S. (36).  The vast majority of human listeriosis cases have been 
reported to occur via consumption of contaminated foods (36), therefore, development 
of more effective methods for controlling the presence of L. monocytogenes in foods is 
a desirable goal.  To that end, various antimicrobial peptides have been investigated as 
a potential means for inhibiting growth of L. monocytogenes in foods (13, 39).  
Bacteriocins are bacterially produced antimicrobial peptides that are generally 
most effective against other bacteria that are genetically similar and present in similar 
ecological niches.  To enhance producer strain self-preservation, bacteriocin 
production is frequently coupled with production of cognate bacteriocin immunity 
proteins (13, 17, 45).  For example, NisI, which provides immunity to nisin, is 
encoded downstream of the nisin biosynthesis genes in Lactococcus lactis (19).  
Previous studies have reported that bacteriocin production can be influenced by 
bacterial environmental stress response pathways such as the RecA-dependent SOS 
response and the ppGpp-dependent stringent response (16).  Bacteriocin production 
and immunity to antimicrobials are hypothesized to enhance the ability of producer 
bacteria to vie for limited nutrients in the presence of competitors (40).  
Lactic acid bacteria (LAB) are recognized as producers of various bacteriocins 
(27, 30).  LAB are commonly present in human foods, and therefore, the bacteriocins 
that they produce, such as pediocin PA-1/AcH, enterocins, and/or sakacins also may 
be present in foods (13).  Currently, only nisin, a class I lantibiotic bacteriocin 
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produced by the lactic acid bacterium Lactococcus lactis, has Generally Recognized as 
Safe (GRAS) status for intentional application as an antimicrobial in the U.S. food 
industry (27).  Nisin creates membrane-spanning pores in the bacterial cell wall, which 
enable dissipation of the cell’s proton motive force (7, 8).  Although, in general, nisin 
has been demonstrated as an effective antilisterial peptide (5), some strains of L. 
monocytogenes have developed resistance to both nisin and pediocin PA-1 (22-24).  L. 
monocytogenes resistance to nisin is a concern to the segments of the food industry 
(e.g., dairy, poultry) that currently use this peptide to control pathogen growth (22).  A 
better understanding of the molecular mechanisms contributing to antimicrobial 
resistance in foodborne pathogens could lead to development of improved food safety 
intervention strategies.  One means to that end is to identify and examine putative 
bacteriocin immunity genes and their physiological roles in protecting the producer 
strain against either endogenously or exogenously produced antimicrobial peptides.  
In a previous study, Kazmierczak et al. (28) identified lmo2570 as a putative 
σB-dependent gene with 45% similarity to the B. subtilis bacteriocin immunity gene 
sdpI (yvaZ) (cmr.jcvi.org), which encodes SdpI.  SdpI is a membrane protein 
conferring resistance to the endogenously-produced antimicrobial peptide SdpC (9, 
18).  Butcher and Helmann (2006) found that while SdpI has a predominant role in 
conferring resistance to SdpC, the B. subtilis regulon contolled by σW, an 
extracytoplasmic function sigma factor (ECF), provides secondary immunity to this 
antimicrobial peptide.  Taken together, these data indicate the importance in 
antimicrobial resistance of both immunity genes and transcriptional level regulatory 
mechanisms as mediated by alternative sigma factors.  
We hypothesized that σB and σL contribute to antimicrobial response in L. 
monocytogenes.  σB has been shown to regulate response to antimicrobial peptides in 
other Gram-positive bacteria.  To illustrate, the B. subtilis σB regulon is up-regulated 
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following treatment with either bacitracin or vancomycin (33).  In a collection of 
teicoplanin-resistant Staphylococcus aureus mutants, the majority of the mutations 
responsible for antimicrobial resistance mapped to rsbW, which encodes the RsbW 
anti-sigma factor that sequesters σB to prevent it from interacting with RNA 
polymerase.  The teicoplanin-resistant strains with mutations in rsbW showed 
increased σB activity relative to their parent strain (the MB33 rsbU mutant strain) or to 
other strains carrying the rsbU wild-type allele (6), providing evidence of a link 
between σB activity and antimicrobial resistance.  σB also has been shown to contribute 
to bacterial stress response regulation in Staphylococcus aureus (10).  L. 
monocytogenes alternative sigma factor σL regulates expression of genes that mediate 
sensitivity to antimicrobials such as the class IIa bacteriocin, mesentericin Y105 (42), 
hence σL also has been associated with antimicrobial response.  Therefore, in the 
studies described below, phenotypic and genotypic assessments were used to 
determine the contributions of σB, σL and Lmo2570 to the L. moonocytgenes response 
to SdpC and nisin.   
 
MATERIALS AND METHODS 
Bacterial strains and growth conditions  
L. monocytogenes parent strain 10403S (serotype 1/2a), and otherwise isogenic 
sigB and sigL single and double null mutants (∆sigB; FSL A1-254, ∆sigL; FSL B2-
124, ∆sigB/∆sigL; FSL B2-127) were used in this study.  L. innocua FSL C2-008 (47), 
L. ivanovii FSL C2-010, L. welshimeri FSL N1-064, and L. seeligeri FSL N1-067 
(Table 3.1) were used to assess intragenus competition with the L. monocytogenes 
parent and mutant strains.  To examine the susceptibility of the L. monocytogenes 
parent and mutant strains to a closely related bacterium that produces an antimicrobial 
peptide, we used strains of B. subtilis that produce SdpC, the bacteriocin whose 
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Table 3.1:  Strains used in this study 
Strain Characteristics Reference or source 
L. monocytogenes 10403S laboratory parent strain Bishop and Hinrichs, 1987 
L. monocytogenes FSL A1-254 10403S ∆sigB Wiedmann et al., 1998 
L. monocytogenes FSL P1-002 10403S ∆lmo2570 This study 
L. monocytogenes FSL B2-124 10403S ∆sigL Chaturongakul, unpublished 
L. monocytogenes FSL B2-127 10403S ∆sigB/∆sigL Chaturongakul, unpublished 
L. innocua FSL C2-008  Woodling and Moraru, 2005 
L. ivanovii FSL C2-010  Wiedmann, unpublisheda 
L. welshimerii FSL N1-064 
 
Fish processing plant 
environment 
L. seeligeri FSL N1-067 
 
Fish processing plant 
environment 
B. subtilis PY79 prototroph, parent strain Youngman et al., 1984 
B. subtilis EG351 PY79 Pspac-hy-sdpABC Butcher and Helmann, 2006 
aIsolate kindly provided (as USDA 2717) by I. Wesley, USDA-ARS  
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 cognate immunity gene is predicted by sequence similarity to be homologous to L. 
monocytogenes lmo2570.  These strains included B. subtilis prototroph (PY49) (48) 
and its mutant EG351 (PY79 Pspac-hy-sdpABC) (gift of Dr. J. Helmann, Dept of 
Microbiology, Cornell University), which expresses SdpC under control of an 
inducible promoter.   
L. monocytogenes strains were grown in brain heart infusion broth (BHI; 
Difco, Sparks, MD) at 37ºC with shaking (250 rpm) overnight (16-18 h), then were 
subcultured (1:100) and grown as described below for each experiment.  B. subtilis 
strains were grown in Luria-Bertani (LB) broth as described for L. monocytogenes, 
unless otherwise stated.  The ∆sigB/∆sigL strain grew more slowly than the 10403S, 
∆sigB; and ∆sigL strains, requiring an additional incubation time of ~30 minutes to 
reach the same OD600.   
Mutant construction  
An in-frame 543 base pair deletion within lmo2570 was created in L. 
monocytogenes 10403S using splicing-by-overlap extension (SOE) PCR and allelic 
exchange mutagenesis (25).  Primers used were 5’-GGA AGC TTT AAG GCA CTG 
TGA GCC TGG-3’ (lmo2570 SOEA), 5’-TCA TAC TAG GAA ATA TAC CAA C-
3’(lmo2570 SOEB), 5’-GTT GGT ATA TTT CCT AGT ATG ATT ATT GTT GTT 
G-3’(lmo2570 SOEC), 5’-GGG GTA CCT CAG GTT CAC TGG CAG CTA G-3’ 
(lmo2570 SOED).  Primers were synthesized by IDT Technologies (Coralville, IA).  
Allelic exchange mutagenesis was confirmed through PCR and subsequent DNA 
sequencing, the latter of which was performed by the Cornell BioResource Center 
(Ithaca, NY).  The Δlmo2570 mutation did not affect growth rate of the mutant strain 
relative to the 10403S parent strain when both were grown in BHI at 37ºC with 
shaking at 250 rpm (data not shown). 
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Spot-on-lawn Assays 
Spot-on-lawn assays were performed in triplicate as described by (9).  Briefly, 
to create lawns, 100µl of a given strain, (i.e., 10403S, Δlmo2570, ΔsigB, ∆sigL, or 
∆sigB/∆sigL) that had been grown to an optical density of OD600= 0.4 was inoculated 
into 2 ml of 0.7% LB soft agar that had been tempered at 50ºC.  To induce Pspac-
regulated transcription of sdpABC when EG351 was used as the spotting strain, 1mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) also was added to the tempered agar that 
had been inoculated with bacteria.  Each mixture was then poured into one well in an 
8-well rectangular multidish (26mm x 33mm; Nunc, Rochester, NY).  The plates were 
then dried in a laminar hood for 30 minutes.  Subsequently, 4µl of the strain being 
assessed for bacteriocin production (e.g., 10403S, PY79 or EG351), which had been 
grown to an OD600= 0.6, was spotted on the agar in the middle of each well.  The 
plates were covered with lids and incubated in a moist container at 37ºC for 22-24 
hours.  In addition to the 10403S, PY79 or EG351 test strains, isolates representing 5 
Listeria species also were used as spotting strains to determine if the lawn strains 
would demonstrate sensitivity to bacteria representing different species within the 
same genus (Table 3.1).  Sensitivity of lawns to potential bacteriocin producer strains 
was assessed by measuring the zone of inhibition (zoi) around the growth of the 
spotted strain.  Radii of zoi were determined by measuring the diameters of both the 
spotted colony and the surrounding zoi in pixels (px).  The diameter of the spotted 
colony was then subtracted from the diameter of the zoi and the resulting product was 
divided by 2 (to yield a radius).  Measurements were performed using Adobe® 
Photoshop® CS (Adobe Systems Incorporated, Mountain View, CA.).  
Radii of zoi produced on the various lawn strains were initially compared to 
zoi produced on the 10403S reference lawn using one-way ANOVA with Dunnett’s t-
test, using SAS® 9.0 (SAS Institute, Inc., Cary, NC).  To determine if there were 
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statistically significant interaction effects between the sigB and the sigL deletions, a 
two-way ANOVA (with Tukey’s adjustment for multiple comparisons) was 
performed.  In this model, the dependent variable was zoi radius, the independent 
variables included sigB + sigL + sigB*sigL + replicate.  The factors “sigB” and “sigL” 
in the model indicate the presence or absence of that gene in the strains tested.  An 
adjusted p<0.05 was considered significant in this and all other statistical analyses. 
Nisin MIC determination 
The objective of this experiment was to determine a minimal inhibitory 
concentration of nisin for log phase L. monocytogenes to enable selection of an 
appropriate sub-lethal concentration for subsequent qRT-PCR experiments.  Nisin’s 
solubility and activity are optimal at pH 3 and 3.5, respectively (1), therefore, nisin is 
typically dissolved in an acidified solution prior to use (26, 31).  As σB expression and 
activity are induced at low pH (3, 44), we predicted that addition of nisin in an 
acidified solution to the various cultures would up-regulate expression of the σB 
regulon, thus conferring a survival advantage to the wildtype over the ∆sigB strain (20, 
21, 46) and, hence, confounding interpretation of our experimental results.  Therefore, 
to avoid induction of σB activity, nisin was dissolved in sterile distilled water 
(1000AU/ml) and the pH of the final solution was adjusted to 7.0 using 0.01N sodium 
hydroxide.  Nisin solutions at pH 7.0 were used throughout these experiments.  The 
nisin solutions were filter sterilized with a 0.2µm, 25mm syringe filter (NALGENE®, 
Thermo Fisher Scientific, Waltham, MA) and diluted to the test concentrations.  The 
minimum inhibitory concentration (MIC) of nisin (Sigma; St. Louis, MO) was 
determined for all strains of L. monocytogenes by measuring absorbance at OD600 
using a FusionTM Universal Microplate Analyzer (PerkinElmer; Shelton, CT).  Strains 
were grown overnight, subcultured 1:100, and grown to OD600=0.4.  Strains were 
inoculated to a final concentration of 1x104 CFU/well into 96-well round bottom 
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microplates (Costar, Corning, NY) and the edges were sealed with Parafilm® (Alcan 
Packaging; Neenah, WI) to prevent evaporation.  OD600 measurements were taken 
following 24 h incubation at 37ºC with shaking.  The lowest concentration that 
inhibited growth for all strains after a 24 hr incubation in a 96 well plate format was 
100AU nisin/ml, as determined in three replicate trials.  Therefore, a sub-lethal 
concentration of 75AU nisin/ml was used for TaqMan qRT-PCR assays. 
Total RNA isolation 
L. monocytogenes 10403S and ΔsigB were grown to logarithmic phase 
(OD600=0.4) and collected after (i) incubation for 10 min following addition of nisin in 
sterile distilled water to yield a final concentration of 75AU/ml nisin; (ii) incubation 
for 10 min following addition of an equivalent volume of sterile distilled water 
without nisin; (iii) incubation for 10 min without any addition.  RNA isolation and 
purification was performed as previously described (41, 44), except that DNase 
treatments were performed using TURBOTM DNase (Ambion, Austin, TX) following 
the manufacturer’s instructions.  Total nucleic acid concentrations and purity were 
estimated using absorbance readings (260 nm/280 nm) on a NanoDropTM ND-1000 
spectrophotometer (NanoDrop Technologies, Rockland, DE). 
Quantitative Reverse-Transcriptase PCR (qRT-PCR) 
Transcript levels of lmo2570, as well as of two housekeeping genes, rpoB and 
gap, were quantified using TaqMan primers and probes and the ABI Prism® 7000 
Sequence Detection System (Applied Biosystems, Foster City, CA) as previously 
described (29).  Data were analyzed using the ABI Prism® 7000 Sequence Detection 
System (SDS) software (Applied Biosystems) as previously described by Sue et al. 
(44).  Primer Express® 1.0 software (Applied Biosystems) was used to design 
oligonucleotide primers and TaqMan probes for lmo2570:  forward primer (5’- AAG 
TGG CGG TGC ATT TCG-3’), reverse primer (5’-TAA GCC AAG CCA CTT TTG 
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CAT-3’), probe (6FAM 5’-ACG GAC TTC TCC CCA GAT-3’ MGB-NFQ).  Primers 
and probes for gap and rpoB were previously described (43, 44), respectively.  
Transcript levels of lmo2570, as determined by qRT-PCR, were log10 
transformed and then normalized to the geometric mean of transcript levels from the 
housekeeping genes rpoB and gap as previously described (29).  Statistical analyses of 
normalized lmo2570 transcript levels were performed using one-way ANOVA and 
Tukey’s studentized range (HSD) test, performed in SAS® 9.0 (SAS Institute).   
Nisin survival assay 
 The objective of this assay was to measure relative survival characteristics of 
stationary phase L. monocytogenes 10403S, ΔsigB, ΔsigL, ΔsigB/ΔsigL,and Δlmo2570 
strains in the presence of an initially lethal concentration of nisin (150AU/ml nisin).  
Strains were grown in BHI at 37oC with shaking overnight, followed by a 1% 
subculture and growth to logarithmic phase (OD600=0.4), followed by a second 
subculture and growth to stationary phase (OD600=1.0 +3 hours), followed by a third 
1% subculture (0.5ml into 50ml, final concentration of ~2x107 CFU/ml) in a 300 ml 
flask (Bellco, Vineland, NJ).  Nisin (150 AU/ml, pH 7.0) was added to the BHI and 
cultures were incubated at 37oC with shaking for an additional 9 h.  Bacterial numbers 
were determined prior to and after the addition of nisin.  Specifically, samples were 
taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 9 h post-addition and spiral plated on brain heart 
infusion (BHI) agar using a Spiral Biotech Autoplate® 4000 (Spiral Biotech; 
Norwood, MA).  Colonies were enumerated with a QCountTM (Spiral Biotech) after 24 
h incubation at 37°C.  Colony counts were transformed to log10 CFU/ml.  
Data from the nisin survival assay were used to calculate two parameters: (i) 
bacterial reduction after 0.5 h of nisin exposure; and (ii) growth rate during recovery 
and re-growth (between 1 and 9 h after nisin exposure).  Linear regression was used to 
determine the slope representing the change in bacterial numbers for each strain from 
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1 h to 9 h (i.e., the period when viable cell numbers were increasing [re-growth]); this 
value represents the bacterial growth rate in log10 growth/h.  Statistical analyses were 
then performed on both parameters.  First, a one way ANOVA (with Dunett’s t-test or 
Tukey’s studentized range [HSD] test) was performed to determine if (i) bacterial 
reduction or (ii) growth rate differed between the mutant strains and the parent strain.  
To determine if there were statistically significant interaction effects between the sigB 
and the sigL deletions, a two-way ANOVA (with Tukey’s adjustment for multiple 
comparisons) was performed.  In this model, the dependent variable was either (i) 
bacterial reduction after nisin exposure or (ii) growth rate during re-growth; the 
independent variables included sigB + sigL + sigB*sigL + replicate.  The factors 
“sigB” and “sigL” in the model indicate the presence or absence of that gene in the 
strains tested.   
 
RESULTS 
No intragenus competition was evident between L. monocytogenes and the 
other Listeria strains tested (Table 3.1).  Specifically, no zones of inhibition occurred 
between any of the listerial species that were used as spotting strains (L. innocua, L. 
ivanovii, L. welshimeri, or L. seeligeri) and any of the L. monocytogenes lawn strains 
(10403S, ∆sigB, ∆sigL or ∆sigB/∆sigL; data not shown). 
 
lmo2570 is σB, but not σL dependent and does not contribute to resistance to nisin 
or SdpC  
qRT-PCR was initially used to determine whether either σB or σL contributes to 
transcription of lmo2570, a putative bacteriocin immunity gene (Figure 3.1).  lmo2570 
transcript levels were consistently and significantly lower in the ΔsigB strain as 
compared to the 10403S parent strain (p<0.05; Figure 3.1), indicating σB-dependent 
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Figure 3.1: Normalized log transformed lmo2570 transcript levels for L. 
monocytogenes 10403S (grey bars), ΔsigB (black bars) and ΔsigL (hatched bars).  
Transcript levels were determined by qRT-PCR using RNA isolated from logarithmic 
phase (OD600= 0.4) L. monocytogenes that had been: (i) incubated for 10 min 
following addition of nisin in sterile distilled water to yield a final concentration of 
75AU/ml nisin; (ii) incubated for 10 min following addition of an equivalent volume 
of sterile distilled water without nisin; or (iii) incubated for 10 min without any 
addition.  Transcript levels were log transformed and normalized to the geometric 
mean of the transcript levels for the housekeeping genes rpoB and gap.  Values 
represent mean transcript levels from three independent RNA collections; error bars 
indicate one standard deviation from each mean.  Overall ANOVA (GLM) showed a 
significant effect of the factor “strain”, but no effect of the factor condition (i.e., “no 
addition”, “addition of water”, or “addition of nisin”).  Tukey’s test showed 
significantly lower transcript levels for lmo2570 in the sigB strain as compared to 
the parent strain; transcript levels did not differ significantly between the sigL strain 
and the parent strain.
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 transcription of lmo2570.  While lmo2570 transcript levels were consistently higher in 
the ΔsigL strain as compared to the parent strain, this difference was not significant 
(p>0.05; Figure 3.1).  The presence of nisin at a sub-lethal concentration (75 AU/ml) 
did not affect lmo2570 transcript levels (Figure 3.1).  Normalized lmo2570 transcript 
levels in 10403S were low, ranging from 0.007 to 0.034.  To put these low lmo2570 
transcript levels into biological context, in 10403S, ~0.02 transcripts of lmo2570 were 
present relative to the mean transcript levels of the highly expressed housekeeping 
genes, rpoB and gap, as indicated in Figure 3.1.  The lmo2570 transcript levels 
observed in the present study are on the same order of magnitude as those reported 
previously for other σB-dependent genes (e.g., opuCA and bsh (11)). 
Spot-on-lawn assays were used to compare the sensitivities of L. 
monocytogenes 10403S and Δlmo2570 to SdpC, the antimicrobial peptide whose 
cognate immunity gene shares amino acid similarity with Lmo2570.  Specifically, B. 
subtilis PY79 (which naturally produces SdpC) and B. subtilis EG351 (which 
overexpresses SdpC in the presence of IPTG) were spotted on lawns of either 10403S 
or Δlmo2570.  Zones of inhibition for 10403S and Δlmo2570 (Table 3.2) did not differ 
significantly (p>0.05), indicating that lmo2570 does not contribute to SdpC resistance.  
Neither 10403S nor Δlmo2570 showed inhibition by 10403S (Table 3.2) or by any 
other Listeria species (data not shown), indicating absence of intragenus inhibition, at 
least among the strains tested.   
To characterize the responses of stationary phase L. monocytogenes 10403S 
and Δlmo2570 to nisin, we evaluated survival of ~ 2 X 107 CFU/mL 10403S or 
Δlmo2570 in BHI in the presence of 150 AU nisin /ml (Figure 3.2).  Exposure to nisin 
for 30 min led to 4.0 and 3.9 log reductions in bacterial numbers for 10403S and 
Δlmo2570, respectively (Figure 3.2), indicating no difference in nisin susceptibility 
between these strains.  After the initial killing by nisin, bacterial numbers increased 
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Table 3.2: Spot-on-lawn assay results 
Strain spotteda 
Mean zone of inhibition radii (SD) for L. monocytogenes strainsb 
10403S ∆lmo2570 ∆sigB ∆sigL ∆sigB/∆sigL 
L. monocytogenes 
10403S 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
B. subtilis PY79 11.8 (1.6) 10.0 (2.2) 11.5 (4.9) 16.7 (0.6) 20.5* (2.3) 
B. subtilis EG351 
(IPTG) 13.5 (3.9) 8.3 (2.9) 28.2* (1.6) 20.7* (5.3) 32.0* (2.6) 
a Strains spotted on the lawns are listed in left column; the average zoi radius around each spot 
is shown for each lawn, with standard deviations (SD) in parentheses. 
b Radii were determined from three independent experiments by measuring diameters of the 
zones of inhibition (zoi) in pixels using Adobe® Photoshop® CS; “*” indicates values that are 
significantly different (P<0.05; one way ANOVA with Dunnett’s t-test) from the zoi produced 
on the L. monocytogenes 10403S lawn 
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Figure 3.2: Viable numbers of stationary phase L. monocytogenes 10403S, 
Δlmo2570, ΔsigB, ΔsigL and ΔsigB/ΔsigL at various time points following 
exposure to 150 AU/ml nisin.  Values are reported as log CFU/ml.  Data shown 
represent the average of four independent experiments; error bars represent one 
standard deviation from each mean. 
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 between 1 and 9 h post-nisin exposure, reflecting growth of cells that had survived 
nisin exposure.  Specifically, after 9 h, bacterial numbers were 6.9 and 6.6 log for the 
parent strain and Δlmo2570, respectively, further supporting that Δlmo2570 and 
10403S susceptibilities to nisin do not differ.  
 
σB and σL both contribute to resistance to the SdpC antimicrobial peptide 
produced by B. subtilis  
Spot-on-lawn assays were used to compare the sensitivities of L. 
monocytogenes 10403S, ∆sigB, ∆sigL, and ∆sigB/∆sigL to the antimicrobial peptide 
SdpC.  The zones of inhibition (zoi) produced by B. subtilis PY79 did not differ 
between L. monocytogenes 10403S and ∆sigB or ∆sigL; the zoi produced by PY79 on 
the ∆sigB/∆sigL lawn was significantly larger than the zoi produced on 10403S 
(p<0.05; Table 3.2), suggesting the possibility that σB and σL contribute to SdpC 
resistance in an additive fashion.  B. subtilis EG351 produced significantly larger zoi 
on ∆sigB (28.2 ± 1.6 px), ∆sigL (20.7 ± 5.3 px) and ∆sigB/∆sigL lawns (avg 32.0 ± 2.6 
px), as compared to the zoi produced on 10403S (13.5 ± 3.9; Table 3.2).  Two-way 
ANOVA analyses of zoi data showed no significant “sigB*sigL” interaction effect on 
SdpC sensitivity (p>0.05), further supporting the notion of additive (as compared to 
multiplicative) contributions of σB and σL to SdpC resistance.  Overall, results from 
this assay indicate that alternative sigma factors σB and σL both contribute to resistance 
to SdpC.  
 
σB and σL both contribute to response to the bacteriocin nisin 
A 30 min exposure to nisin (150AU/ml) resulted in a 4.0 log reduction in 
bacterial numbers for stationary phase 10403S.  By comparison, reduction of ∆sigB 
bacterial numbers was significantly less (3.0 log reduction; p<0.05; Figure 3.2), 
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indicating increased nisin resistance of this strain relative to that of 10403S.  Bacterial 
numbers for the ∆sigL and ∆sigB/∆sigL strains were reduced by 3.9 and 4.5 log; these 
reductions were not significantly different from that of 10403S (p>0.05; Dunnett’s t-
test).  Interestingly, log reduction for the ∆sigB/∆sigL strain was significantly (p>0.05; 
Tukey’s HSD) greater (4.5 log) as compared to the ∆sigB strain (3.0 log reduction), 
indicating a significant effect of the sigL deletion on nisin killing in a ∆sigB 
background.  Based on the reductions in bacterial numbers between 0 and 0.5 h, two-
way ANOVA analyses found a significant “sigL*sigB” interaction effect on survival 
following nisin exposure, indicating that the effect of one sigma factor on survival 
differs depending on the presence or absence of the other sigma factor.  
After initial killing by nisin, all strains showed re-growth between 1 and 9 h 
post nisin exposure.  Rates of re-growth, as represented by the slopes of the graphs 
between 1 and 9 h post-exposure, were compared among the strains.  While the 
growth rate for the ∆sigL strain (0.39 log CFU/h) was not significantly different from 
that of the parent strain (0.41 log CFU/h), both the ∆sigB and the ∆sigB/∆sigL strains 
showed significantly slower growth rates (0.36 log CFU/h for both; p<0.05, Dunett’s 
t-test) as compared to the parent strain.  Although no significant “sigB*sigL” 
interaction effect on nisin survival was identified by two-way ANOVA analysis, the 
sigB deletion had a significant effect on growth rate, with sigB deletion strains (i.e., 
∆sigB, ∆sigB∆sigL) showing slower growth rates as compared to the corresponding 
strains with intact sigB genes.   
 
DISCUSSION 
We hypothesized that alternative sigma factors σB and σL and the hypothetical 
bacteriocin immunity gene, lmo2570, contribute to L. monocytogenes antimicrobial 
response.  This hypothesis was based on previous observations including: (i) σB and its 
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homolog σF contribute to antimicrobial response in other Gram-positive organisms (6, 
33, 37), (ii) L. monocytogenes σL controls sensitivity to class IIa bacteriocins, 
mesentericin Y105, pediocin PA-1, and enterocin A, and (iii) the putative σB-
dependent lmo2570 has sequence homology to the B. subtilis bacteriocin immunity 
gene, sdpI.  To test our hypothesis, we assessed the sensitivities of strains with null 
mutations in sigB, sigL, sigB/sigL, or lmo2570 to the antimicrobial peptides SdpC and 
nisin.  We also characterized transcription of lmo2570 in 10403S, ∆sigB, and ∆sigL 
strains exposed to a sub-minimal inhibitory concentration of nisin.  Our results show 
that (i) while lmo2570 is σB-dependent, it does not contribute to resistance to SdpC or 
nisin; and (ii) both σB and σL contribute to resistance to the antimicrobial peptide 
SdpC, as shown by results from spot-on-lawn assays.  In addition, both σB and σL 
affect L. monocytogenes sensitivity to nisin in broth survival assays.  Specifically, 
while loss of only sigB renders the resulting strain more resistant to nisin than the 
parent strain, loss of sigB in a ∆sigL background leads to reduced nisin resistance 
relative to the original parent strain.   
 The effects of antimicrobial peptides on L. monocytogenes appear to differ 
depending on the class of peptide, the strain, initial number of bacteria, growth phase, 
and the assay used for evaluation.  To illustrate, σB was reported previously to 
contribute to L. monocytogenes tolerance to nisin or lacticin 3147 in broth assays (4), 
but not to nisin, lacticin 3147, or sakacin A resistance in agar overlay assays (4, 38).  
Moorhead and Dykes (2003) showed that a L. monocytogenes serotype 1/2a wildtype 
strain was less resistant to nisin than a serotype 4c wildtype strain, suggesting 
differences in antimicrobial sensitivities among strains.  It is also likely that other 
environmental stresses (in addition to the presence of the antimicrobial peptide) 
imposed upon the cells also evoke differential phenotypic responses from the cells 
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(e.g., exposure to low pH induces σB activity in L. monocytogenes), which may 
provide cross-resistance to multiple stresses (21).  
 
lmo2570 is σB-dependent, but does not contribute to antimicrobial resistance 
L. monocytogenes Lmo2570 is 45% similar at the amino acid level to the B. 
subtilis immunity protein SdpI, which confers immunity against SdpC (9, 18), 
therefore, we hypothesized that lmo2570 may play a role in antimicrobial immunity in 
L. monocytogenes.  lmo2570 was predicted as σB-dependent in previous microarray 
experiments (28).  As previous reports have shown bacteriocin immunity genes can 
contribute to resistance to multiple antimicrobials (35), in addition to examining its 
role in SdpC resistance, we also tested the contributions of lmo2570 to resistance to 
the commercially available bacteriocin, nisin.  The ∆lmo2570 strain did not show 
reduced sensitivity to either SdpC or nisin.  Exposure to nisin did not induce 
transcription of lmo2570 in either the wildtype or any of the mutant strains.  lmo2570 
thus does not appear to be important for SdpC or nisin resistance in L. monocytogenes.  
A role for this gene in resistance to other bacteriocins or in contributing to nisin and 
SdpC resistance under environmental conditions not tested here cannot be excluded by 
our data, however.  Our confirmation of lmo2570 as σB-dependent suggests a role for 
lmo2570 in L. monocytogenes survival or growth under conditions that remain to be 
defined.  
 
σB and σL both contribute to L. monocytogenes response to SdpC and nisin 
 We found clear evidence that alternative sigma factors σL and σB both 
contribute to SdpC resistance.  Specifically, as determined in a spot-on-lawn assay, we 
showed that both the ∆sigB and the ∆sigL strains were significantly more susceptible 
to the bactericidal effect of the antimicrobial peptide SdpC produced by B. subtilis 
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EG351 than the otherwise isogenic 10403S parent strain.  Characterization of a 
∆sigB/∆sigL double mutant strain suggested that deletion of both genes had an 
additive, but not an interactive, effect on SdpC resistance.  However, deletions of both 
∆sigB and ∆sigL had an interactive effect on L. monocytogenes resistance to nisin.  
Specifically, while the ∆sigB/∆sigL strain showed decreased resistance to nisin as 
compared to the ∆sigB strain, the ∆sigB strain showed increased resistance to nisin as 
compared to the parent strain, which has both sigB and sigL intact.  The interactive 
effect observed following the loss of both sigB and sigL may indicate that at least 
some genes important for recovery and re-growth following nisin exposure are co-
regulated, either directly or indirectly, by these alternative sigma factors.  We also 
found that re-growth of both the ∆sigB and the ∆sigB/∆sigL strains following nisin 
exposure was slower than that of the parent strain, consistent with previous 
observation that σB is important for B. subtilis recovery following rifampin treatment 
(2).  The overall observation that a deletion of the gene encoding σL (i.e., a single 
deletion) does not affect L. monocytogenes resistance to nisin is consistent with 
observations by (15), who reported that σL (which has also been designated as RpoN) 
is not involved in L. monocytogenes nisin resistance.  Relative to its otherwise 
isogenic parent, a ∆rpoN L. monocytogenes strain (i.e., a strain lacking σL) has 
previously shown increased resistance to the class IIa nonlantibiotic bacteriocins 
mesentericin Y105, pediocin PA-1, and enterocin A (15, 42), consistent with our 
findings that σL contributes to resistance to some bacteriocins (i.e., SdpC).  Our 
findings, as well as previous findings by others (15), thus support that different 
regulatory elements are critical for the ability of L. monocytogenes, and other bacteria, 
to respond to different bacteriocins, a notion consistent with the diverse nature of this 
group of antibacterial compounds. 
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 Overall, our data indicate that σB and σL both contribute to the ability of L. 
monocytogenes to respond to antimicrobials.  Regulatory interactions among multiple 
alternative sigma factors also have been shown to contribute to antibiotic resistance in 
B. subtilis.  Specifically, three (σM, σW, and σX) of the seven B. subtilis ECF 
alternative sigma factors have overlapping regulons that contribute to antibiotic 
resistance, as demonstrated by the greatly enhanced sensitivity of a triple MWX 
mutant to various antimicrobials, including nisin (32).  Strains bearing single or 
double mutations in the genes encoding these alternative sigma factors displayed 
considerably less antimicrobial sensitivity than the strain with the triple mutation (32).  
Thus, in combination with previous studies, our data support a model in which 
multiple alternative sigma factors contribute to regulatory networks important for fine-
tuning transcriptional regulation of gene expression to help optimize bacterial cell 
resistance to antimicrobial peptides.  
 
CONCLUSIONS 
Alternative sigma factors have been shown to regulate genes and operons 
critical for resistance to antimicrobials in various bacteria, including B. subtilis, L. 
monocytogenes, Salmonella enterica serovar Typhimurium, S. aureus, and Vibrio 
cholerae (9, 14, 34, 42, 49).  Our data indicate that σB and σL, as well as the 
simultaneous presence of both σB and σL, contribute to antimicrobial response in L. 
monocytogenes in a manner that is dependent on the antimicrobial that is present.  The 
results reported in this study provide further evidence of the importance of regulatory 
networks for fine-tuning L. monocytogenes responses to changing environmental 
conditions (12).  
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CHAPTER 4 
IDENTIFICATION OF A SMALL MOLECULE THAT INHIBITS THE L. 
MONOCYTOGENES σB REGULON AND ITS VIRULENCE ASSOCIATED 
FUNCTIONS 
 
ABSTRACT 
For some bacteria, current treatment options are minimally effective. In fact, for Listeria 
monocytogenes, which causes the rare but potentially deadly disease listeriosis, the 
mortality rate remains at 20-30% despite the use of antibiotics. This indicates the need 
for the identification of new drug targets for increasing efficacious treatment 
alternatives.  The L. monocytogenes alternative stress response sigma factor σB 
represents a conserved biological target, highly relevant to several important Gram-
positive human pathogens. In these pathogens, σB regulates virulence genes and 
contributes to survival under host-associated stress conditions, such as those 
encountered in the gastrointestinal lumen. Using a high-throughput cell-based format to 
identify inhibitors of L. monocytogenes σB, approximately 57,000 compounds were 
screened from a compilation of natural and synthesized small molecules. Subsequent 
screening identified a compound on which transcriptional and phenotypic profiling were 
performed. The compound, sigmastatin (IC50=3.5µM), showed targeted down regulation 
of the majority of the σB regulon yielding a transcriptional profile similar to a genetic 
knockout of sigB. From the genes downregulated by sigmastatin, 75% were σB 
dependent. Specifically, according to microarray analysis, of the 208 genes that were 
downregulated as a result of treatment with this compound, 156 were positively 
regulated by σB, including key virulence and stress response genes such as inlA, inlB, 
bsh, hfq, opuC, bilE.  This compound also hinders L. monocytogenes invasion in human 
intestinal epithelial cells.  Interestingly, this small molecule was also capable of 
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inhibiting σB activity in Bacillus subtilis. The ability of sigmastatin to produce a 
chemical knockout phenotype comparable to a genetic knockout supports its usefulness 
as a biological probe. Not only does this allow us to explore the molecular 
underpinnings of L. monocytogenes that drive virulence and stress response, but it also 
helps to elucidate complex regulatory networks in order to develop better methods to 
control this pathogen.  
 
INTRODUCTION  
Listeria monocytogenes is the causative agent of a rare, but potentially fatal, 
foodborne disease called listeriosis.  Listeriosis has a high case fatality rate, 
accounting for ~10% of all deaths from foodborne diseases in the US (61).  According 
to the Centers for Disease Control, in 2008 the incidence of listeriosis infections had 
not declined in the US in the preceding three years (1). Furthermore, there has been an 
increasing incidence of listeriosis in Europe since 2004 (33). These data suggest the 
need for development of more effective preventive strategies and interventions. 
L. monocytogenes can transition from a saprotrophic existence under a wide 
range of environmental conditions (70) to intracellular infection in a diverse array of 
hosts (101).  The ability of L. monocytogenes to transform from saprotroph to 
intracellular pathogen is influenced by regulatory networks that control virulence 
factor expression in response to environmental signals (18).  σB is one important 
component of a network that links environmental stress survival and virulence in L. 
monocytogenes (72, 98).  σB networks contribute to transmission of L. monocytogenes, 
including during the gastrointestinal and systemic stages of infection (14, 30).   
Sigma (σ) factors are dissociable subunits of prokaryotic RNA polymerase.  
The association of a specific alternative sigma factor (such as σB) with core RNA 
polymerase under appropriate environmental conditions reflects a transcriptional 
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regulatory mechanism that can rapidly reprogram global gene expression patterns in 
response to environmental signals.  Through microarray analyses, the σB regulon in L. 
monocytogenes has been reported to include >150 genes (45, 77).  Because of its key 
role in L. monocytogenes stress resistance and virulence, and hence, in transmission of 
this pathogen, σB is a promising target for investigation and development of novel 
therapeutic intervention strategies. 
Identification of novel anti-infective agents by screening small-molecule 
libraries for inhibitors or perturbational agents of specific targets is one promising 
approach for development of new therapeutics.  Such strategies have been used to 
identify inhibitors of virulence-related two-component regulators and quorum sensing 
in Pseudomonas aeruginosa (36, 37, 83), inhibitors of the Type 3 Secretion System in 
multiple Gram-negative bacteria (3, 44, 69), inhibitors of anthrax lethal factor in 
Bacillus anthracis (41, 75, 84), and inhibitors of the virulence regulator ToxT in 
Vibrio cholerae (40), among others.  To test the hypothesis that a small molecule can 
inhibit σB activity, a high-throughput assay was used to screen multiple small-
molecule libraries.  The ability of the most promising compound to inhibit σB activity 
was further assessed by small molecule binding microarray analysis, whole genome 
microarray, qRT-PCR, and phenotypic profiling, including bile salt hydrolase activity 
and Caco-2 cell invasion assays.  Further, the compound was assessed for its ability to 
inhibit σB activity across genera. 
 
MATERIALS AND METHODS 
Strain and media selection 
As L. monocytogenes opuCA transcription has been clearly established as σB-
dependent (45, 97), an opuCA-gus reporter fusion was selected for monitoring σB 
activity.  The strains used in this study included the L. monocytogenes parent strain 
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10403S (serotype 1/2a)(7), its otherwise isogenic sigB mutant derivative (∆sigB; FSL 
A1-254 (102)), a reporter strain for σB activity (10403S opuCA-gus; FSL S1-063) and 
a negative control reporter strain for σB activity (∆sigB opuCA-gus; FSL S1-059) 
(Table 4.1).  To achieve low background fluorescence, a chemically defined minimal 
medium (76) with 25mM glucose (DMG) (26) was used for the high-throughput 
screen.  Cells were grown in brain heart infusion broth (BHI; Difco, Sparks, MD) for 
phenotypic and transcriptional profiling assays. 
High-throughput Cell-Based Small Molecule Screen  
Primary Cell Based Screen 
The L. monocytogenes opuCA-gus fusion strain FSL S1-063 was used in a cell-
based high-throughput screen (HTS) against ~ 57,000 compounds. As reported at 
ChemBank.Broad.Harvard.edu, compounds came from a multitude of libraries 
including libraries of (i) known bioactive compounds (i.e., SPBio, SMP libraries); (ii) 
synthetic compounds from diversity oriented synthesis (i.e., CMLD, ICCB, PK04, 
Ald1.1-H, Sulf1.1-A libraries); (iii) natural products (i.e., PhilEx, ICBGEx libraries), 
and (iv) pharmaceuticals.  
Multidrop liquid handling robots (Matrix, ThermoFisher) were used to 
dispense 27µl of DMG into black walled clear bottom 384-well plates (Nunc; 
Rochester, NY), then 100nl of ~10mM stock of each small molecule was transferred 
from library stock or source plate to assay plates in a total volume of 30µl (e.g., 8009-
2163 had a stock concentration of 19.3mM, producing a 64.3µM final concentration in 
the well) by the CyBi®-Well Vario pin transfer robot (CyBio AG; Jena, Germany).  
Each source plate contained ~15 dimethyl sulfoxide (DMSO)-only wells as negative 
internal control wells.  All source plates were pinned in duplicate to provide 
experimental replicates (i.e., plates A and B).  Two DMSO base plates were also 
included as external plate controls.  A custom assay plate containing 192 wells of 
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Table 4.1:  Strains used in this study 
Strain Characteristics Reference  
10403S Laboratory Parent Strain Bishop and Hinrichs, 1987 
FSL A1-254 (LM ∆sigB) Control strain, complete 
inhibition of σB activity Wiedmann et al., 1998 
FSL S1-063 (LM opuCA-gus) Reporter strain for σ
B 
activity in L. monocytogenes Ferreira et al., 2003 
FSL S1-059 (LM ∆sigB opuCA-
gus) 
Negative control reporter 
strain for σB activity in L. 
monocytogenes 
Ferreira et al., 2003 
FSL P1-015 (BS PB198 
amyE::pDH32-ctc trpC2) 
Reporter strain for σB 
activity in B. subtilis Boylan et al., 1992 
FSL P1-017 (BS PB345 
amyE::pDH32-ctc sigB∆3::spc 
trpC2) 
Negative control reporter 
strain for σB activity B. 
subtilis 
Boylan et al., 1993 
FSL P1-019 (BS PB252 
amyE::PA-lacZ trpC2) 
Reporter strain for σA 
activity B. subtilis Wise and Price, 1995 
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10403S opuCA-gus strain FSL S1-063 and 192 wells of the otherwise isogenic ΔsigB 
opuCA-gus strain FSL S1-059 was treated with only DMSO, was used as a control.  
After 3µl of L. monocytogenes grown to OD600=0.4 and diluted 1:50, was added to the 
plate containing the compounds, the plates were sealed and incubated for 18 h at 37°C.  
To determine bacterial numbers after the incubation period, absorbance (OD600) was 
measured using a Synergy™ HT Multi-Mode Microplate Reader (BioTek Instruments; 
Winooski, VT) at approximately 18 h.  To prepare the plates for fluorescence 
measurements, black seals (Perkin Elmer; Waltham, MA) were affixed to the back of 
the plates after the T=18 h absorbance readings.  For the GUS assays, cells were lysed 
using 5µl of 2x CelLyticB (Sigma; St. Louis, MO and Protease Inhibitor Cocktail 
(Sigma) mixture (1ml 2x CelLyticB and 0.05ml Protease Inhibitor Cocktail), 
immediately prior to addition of 4µl of 1.6mg/ml 4-methylumbelliferyl β-D 
glucuronide hydrate (4-MUG; Sigma) in DMSO.  Reactions were incubated in the 
dark for 1 h at room temperature (~23oC) then reactions were stopped by addition of 
0.2M Na2CO3 (Sigma).  Fluorescence was read using a Wallac 2102 EnVision™ 
Multilabel Reader (Perkin Elmer) with an excitation wavelength of 355nm and an 
emission of 460nm.  
Statistical analysis of primary screen data 
To identify compounds that inhibited σB activity without affecting L. 
monocytogenes growth, opuCA-directed GUS activity in the presence of each 
compound was calculated by dividing relative fluorescence units (RFU) by cell 
density (in OD600 units) (RFU/OD, (88)) Statistical analyses were conducted in 
collaboration with the Broad Institute and performed as previously described (47, 50). 
Briefly, the median value from the internal DMSO-only wells in a given plate were 
subtracted from raw values of all 12 to 20 internal DMSO-only wells within the same 
assay plate. The resulting scores were used to build a distribution across assay plates 
             71
  
between replicates (i.e., replicate plates A and B), which was used to identify outliers 
within the internal DMSO-only wells (i.e., values that differ from the median by more 
than 2.57 standard deviations). Values for the DMSO-only wells (after removal of 
outliers) were used to calculate an average baseline for each plate. Raw values from 
duplicate plates containing only DMSO inoculated with the wildtype gus fusion strain 
were used to calculate the standard deviation of the baseline value per replicate. The 
average baseline per plate and standard deviation per replicate, together with raw 
values from wells with small molecules, were used to calculate Z scores for each small 
molecule; the Z score represents the deviation of a well with a small molecule from 
the baseline mean (in standard deviation units). The Z score allows interpretation of 
the effect of a small molecule on the activity of σB.  Z scores <-3 standard deviations 
were considered significant, indicating that a given small molecule inhibits the σB. 
Raw and analyzed data were deposited in ChemBank (86, 94).  Z-scores were 
analyzed using the commercial software package Spotfire DecisionSite Analytics 
(TIBCO Spotfire; Somerville, MA) to enable 2 dimensional data visualization and 
identification of positive candidates with high reproducibility.  Compounds that 
generated Z-scores below -3 (based on adjusted RFU/OD data values) were considered 
to inhibit σB
Secondary screen and dose response curve 
 activity.  
Forty-one compounds that appeared to inhibit σB activity (Z-score ≤-3 in both 
replicates) were selected for secondary cell-based screening using the same format and 
reporter fusion as described above.  These compounds were assessed for their abilities 
to interfere with σB activity and to calculate initial IC50 values (i.e., concentration that 
inhibits 50% of σB activity).  Each compound was diluted in a series of six 1/5 
dilutions of the stock concentration. For example, starting from 19.3mM stock, 8009-
2163 was diluted in a series of six 1 to 5 dilutions and pinned into an assay plate. A 
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total of 14 compounds were assessed for follow-up analyses by “drug developability 
criteria” including size/molecular weight, hydrogen bonds, structure-based potential 
toxicity, etc (58). 
Small-Molecule Microarray Screens 
Small-molecule microarrays (SMMs) were printed on glass slides at the Broad 
Institute as described previously (12, 13, 22).  Two different arrays (each slide printed 
with 8,500 small-molecule [SM] spots and 1,500 DMSO control spots) were used for 
our screens.  The immobilized SMs included 8,500 compounds from diversity oriented 
synthesis (DIV06) and 8,500 compounds representing natural products, FDA-
approved drug-like compounds, and known bioactive compounds (NPC1) ((22) 
Chembank.broadinstitute.org).  SMM screening (three replicates) was performed as 
described by Bradner et al. (12).  Briefly, His-tagged σB was purified from E. coli M15 
(kindly provided by W. Goebel (8)).  Slides were incubated at 4°C with PBST (PBS 
plus 0.1% Tween 20) containing 1µg/µl of His-tagged σB and 1 mg/ml BSA.  Slides 
were washed with PBST buffer 3 times. Slides were incubated in Alexa Fluor 647 
labeled anti-His antibody (1:2000 in PBST) for 1 hour at 4°C. Slides were washed 3 
times in PBST and 1 time with PBS. Slides were rinsed with deionized water to 
remove buffer salts and dried by centrifugation at <1000 rpm. Slides were then 
scanned with an Axon 4000B and analyzed using GenePix® Pro 6 image analysis 
software.  Data analyses included (i) assessment of signal-to-noise ratio (SNR) of the 
spot feature; (ii) Z-score calculations based on comparison of signals from compound 
spots compared to signals from DMSO control spots within a slide; and (iii) composite 
Z-score calculations for data from the three replicates.  Spotfire Analytics software 
was used for 3-dimensional data visualization.  Compounds from the DIV 06 library 
with Z-scores ≥ 0.925 or from the NPC1 library with Z-scores ≥ 1.2 were considered 
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potential binders.  Compounds considered for further analysis were identified by both 
SMM and HTS. 
Phenotypic Profiling and qRT-PCR 
The most promising lead compound identified by SMM and HTS (8009-2163) 
was not commercially available.  Therefore, an analog (2-Phenyl-ethenesulfonic acid 
(4-fluoro-phenyl) amide or T0513-8332, FW 277) was obtained from Enamine Ltd. 
(Kiev, Ukraine).  This compound, T0513-8332 (2-Phenyl-ethenesulfonic acid (4-
fluoro-phenyl) amide), designated sigmastatin, has a fluorine substituted for a 
hydrogen in the original compound.  Sigmastatin was dissolved in DMSO to a final 
concentration of 10mM.  The solution was filter sterilized using with a 0.1µm filter 
compatible with DMSO (OMNIPORETM Membrane filter, Millipore Corporation, 
Billerica, MA) which was fitted in a Swinney Stainless 13mm holder for syringe 
filtration (Millipore Corporation).  
Bile Salt Hydrolase (BSH) activity assay 
As the L. monocytogenes bsh gene, which encodes bile salt hydrolase, is σB 
dependent (23, 45, 72, 96), a BSH activity assay was used to determine the optimal 
concentration of sigmastatin needed for σB inhibition. Four- well multidish plates 
(26mm x 33mm; Nunc) containing 6ml of either BHI agar or de Man, Rogosa and 
Sharp (MRS) agar medium (BD Biosciences; San Jose, CA) containing 0.5% (w/v) 
glycodeoxycholic acid sodium (GDCA) salt (Calbiochem®; San Diego, CA) (21) with 
either (i) no sigmastatin; or (ii) 96, 193 or 290 µM (5, 10, 15x the 19.3mM stock 
concentration) of sigmastatin were prepared and allowed to dry overnight.  L. 
monocytogenes 10403S and ∆sigB were grown in BHI broth to exponential phase, 
defined as OD600= 0.4, then 4µl of culture was spotted in parallel on the MRS and BHI 
agars (BHI; Difco, Sparks, MD).  The MRS agar plates were incubated in a BD-
BBL™ GasPak™ Anaerobic system (BD; Franklin Lakes, NJ) containing an activated 
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BD-BBL™ GasPak™ Plus anaerobic system envelope with Palladium Catalyst.  BHI 
plates were incubated aerobically.  Both sets of plates were incubated for 48 hours at 
37°C.  The assay was replicated three times.  
Cell collection and RNA isolation for qRT-PCR and microarray analyses 
L. monocytogenes 10403S and ΔsigB strains were grown overnight in 5 ml of 
BHI broth at 37ºC with shaking (230 rpm), then were sub-cultured twice using a 1% 
(vol/vol) transfer into 5 ml of pre-warmed BHI.  Each time, cells were grown to OD600 
= 0.4.  When the second sub-culture reached OD600 = 0.4, cells were treated with a 
total volume of 76 µl comprised of (i) sigmastatin (to yield final concentrations 
ranging from 1µuM to 128µM) and/or (ii) DMSO, followed immediately by addition 
of either 324µl of (i) 5M NaCl (to yield a final concentration of 0.3M NaCl, an 
osmotic stress that induces σB (77)) or (ii) sterile distilled water.  Treated cultures were 
then incubated at 37ºC with shaking (230 rpm) for 10 min.  Following incubation, a 
2X volume of RNAprotectTM (Qiagen Inc, Valencia, CA.) was added to the treated 
cultures, mixed and held at room temperature for 10 min.  The cells were harvested 
following centrifugation for 10 min at 5000 X g, supernatant was discarded and tubes 
containing cell pellets were stored at -80 ºC.  RNA was extracted and DNase treated 
using Ambion RiboPureTM-Bacteria Kit (Ambion, Austin, TX) according to the 
manufacturer’s instructions.  Total nucleic acid concentrations and purity were 
assessed using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Rockland, DE).  RNA quality was analyzed using the 2100 Bioanalyzer (Agilent 
Technologies; Santa Clara, CA) and only RNA with an integrity number of ≥8 was 
used.  Each treatment was replicated at least 3 times. 
TaqMan qRT-PCR 
Transcript levels from the σB-dependent genes opuCA and gadA, as well as 
from two housekeeping genes, rpoB and gap, were quantified from the harvested RNA 
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using TaqMan primers and probes and the ABI Prism® 7000 Sequence Detection 
System (Applied Biosystems, Foster City, CA) as previously described (46). Data 
were analyzed using the ABI Prism® 7000 Sequence Detection System (SDS) 
software (Applied Biosystems) as previously described by Sue et al. 2004.  Primers 
and probes for gap and rpoB were reported previously (85, 97), respectively. 
Transcript levels from opuCA and gadA were log10 transformed and then normalized 
to the geometric mean of transcript levels from the housekeeping genes rpoB and gap 
as previously described (46).  Statistical analyses of normalized opuCA and gadA 
transcript levels were performed using one-way ANOVA and Tukey’s Studentized 
Range HSD multiple comparison test using SAS® 9.0 (SAS Institute).  
Starting with the primary screen concentration (64µM) of sigmastatin, the 
concentration needed to achieve 50% of maximal inhibition (IC50) was determined by 
measuring log-normalized transcript levels from opuCA collected from cells treated 
with a series of 1:2 dilutions. These data were analyzed using SigmaPlot® 10.0 (Systat 
Software Inc.; Evanston, IL) standard curve analysis under the pharmacology function.  
Invasion Assay   
L. monocytogenes invasion assays using the human colorectal adenocarcinoma 
epithelial cell line Caco-2 (ATCC HTB-37) were performed as described by Garner et 
al. (2006) with minor modifications. Briefly, 5.0 x 104 Caco-2 cells were seeded into 
24-well plates (Costar, Corning, NY) 48 h prior to infection. L. monocytogenes 
10403S and ΔsigB strains were grown overnight in 5 ml of BHI broth at 37ºC with 
shaking (230 rpm), then were sub-cultured twice using a 1% (vol/vol) transfer into 5 
ml of pre-warmed BHI.  Each time, cells were grown to OD600 = 0.4.  When the 
second sub-culture reached OD600 = 0.4, cells were treated with a total volume of 76 
µl comprised of (i) sigmastatin to yield final concentrations of 64µM (primary screen 
concentration) or 8µM (lowest concentration with full efficacy according to qRT-
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PCR) and/or (ii) DMSO, followed immediately by addition of either 324ul of (i) 5M 
NaCl or (ii) sterile distilled water.  Treated cultures were then incubated at 37ºC with 
shaking (230 rpm) for 30 min. For infection, the Caco-2 cells were inoculated with 
approximately 2.0x 107 L. monocytogenes cells; L. monocytogenes numbers used for 
infection were confirmed by plating on BHI agar.  Intracellular L. monocytogenes 
numbers were determined 90 min post infection as previously described (30).  
Invasion efficiency was calculated as the number of bacteria recovered relative to the 
lnumber of bacteria used for inoculation (i.e., Log ([CFU/ml recovered] /[CFU/ml 
inoculated]).  Four biological replicates were each performed in triplicate wells. 
Statistical analysis was performed using one-way ANOVA and Tukey’s studentized 
range (HSD) test, performed in SAS® 9.0 (SAS Institute). 
Whole Genome Microarray  
cDNA labeling and hydbridization 
cDNA labeling was performed as previously described (72) with minor 
modifications.  For cDNA synthesis, 6 μg total RNA was mixed with 3 μg random 
hexamers and incubated for 10 min at 70°C, then held on ice for 5 min.  Superscript 
III RT, Aminoallyl 2'-Deoxyribonucleoside Triphosphates, dithiothreitol, RNaseOUT, 
and buffer were added and the reaction was incubated at 42°C for approximately 17 h. 
The reaction was stopped and purified according to Ollinger et al., 2009 (72).  cDNA 
coupling reactions with CyTM3 or CyTM5  monofunctional fluorescent dyes (GE 
Healthcare UK Ltd; UK) were performed  for 1 h at room temperature. L. 
monocytogenes whole genome microarrays were constructed as previously described 
(15, 77). Microarray hybridization was performed as previously described (72). Array 
data were deposited at the Gene Expression Omnibus (GSE16887). 
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Statistical analysis of microarray data 
Raw intensity values for all probes on each array were normalized using pin-
tip LOWESS (77) in R v.2.2.1 with the LIMMA package.  Signals from two replicate 
probes on each array were averaged and log2 transformations were performed after 
normalization.  Differences in transcript levels between strains were determined using 
a linear model and p values were determined using eBayes.  Differences in transcript 
levels were considered meaningful if they met both adjusted p-values <0.05 
(indicating significant expression), fold changes of ≥2 (indicating differential 
expression) and probe cross-hybridization index (CHI) of >90%. Although lmo0263 
was inhibited by sigmastatin, the CHI was 80% and was not included in our 
assessments. Gene Set Enrichment Analysis (GSEA) (95) was used to identify gene 
sets that were significantly enriched among genes up or down-regulated in a given 
mutant strain.  GSEA was run on the ranked list of Log Fold Change values obtained 
from the fitted normalized data in LIMMA with 1000 permutations and exclusion of 
gene sets with less than 5 or greater than 2000 members.  Genes were classified into 
sets based on the TIGR Comprehensive Microbial Resource (http://cmr.tigr.org) sub-
role categories for L. monocytogenes EGD-e.  False discovery rate q-values less than 
0.25 were considered significant (95).  
β-galactosidase enzyme assays in B. subtilis  
B. subtilis strains P1-015 (PB198 amyE::pDH32-ctc trpC2 (11)) and an 
otherwise isogenic sigB mutant P1-017 (PB345 amyE::pDH32-ctc sigB∆3::spc trpC2 
(10)) were used as reporter strains for measuring σB activity (Table 4.1). The Pctc-lacZ 
reporter fusion was chosen for monitoring σB activity as ctc transcription has been 
clearly established as σB –dependent (65).  A B. subtilis strain P1-019 (PB252 
amyE::PA-lacZ trpC2 (104)) was used to assess whether treatment with 64µM of the 
compound affected the housekeeping sigma factor σA in B. subtilis. Strains were 
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grown overnight in 5 ml of buffered Luria Bertani (LB) broth at 37ºC with shaking 
(230 rpm), then were sub-cultured twice using a 1% (vol/vol) transfer into 5 ml of pre-
warmed LB.  Each time, cells were grown to OD600 = 0.4.  When the second sub-
culture reached OD600 = 0.4, cells were treated with 76µl of (i) sigmastatin and DMSO 
(final 8 or 64µM) or (ii) DMSO only, followed immediately by addition of 324µl of 
(i) 5M NaCl (final 0.3M) or (ii) sterile distilled water.  Treated cultures were then 
incubated in the 37ºC shaking incubator for 30 min.  OD600 was recorded and 0.2ml of 
the culture was added to a tube containing 2.8ml Z-buffer.  0.02ml toluene was added 
to permeabilize the cells.  Pre-warmed 0.4ml of 4mg/ml ortho-nitrophenyl-β-
galactoside (ONPG) was added and the time of addition was noted.  The reaction 
proceeded for 85 minutes, after which, 1ml of 1M sodium carbonate was added to stop 
the reaction. OD420 was read and Miller Units were calculated (106). Statistical 
anlaysis of β-galactosidase activity was assessed using one-way ANOVA and Tukey’s 
studentized range (HSD) test, performed in SAS® 9.0 (SAS Institute). 
 
RESULTS 
A high-throughput cell-based screen identifies promising small molecules that 
interfere with  σB activity  
A high-throughput cell-based screening assay (HTS) was developed, validated, 
and used to identify small molecules that inhibit σB activity.  The premise of the 384-
well plate-formatted assay was that a compound that reduced β-glucuronidase activity 
generated by a reporter fusion between the σB–dependent opuCA promoter and gus 
(encoding GUS) (96) without affecting L. monocytogenes growth (according to plate 
assay) would be a candidate for further consideration (Chembank Screening Project: 
SigBInhibition).  Based on this primary screen (Figure 4.1), 41 compounds were 
identified that inhibited σB activity (Z score ≤ -3 in both replicates for RFU and 
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Figure 4.1: Scatterplot of high-throughput screen. Scatterplot of Z-scores 
calculated from GUS activities (in relative fluorescent units [RFU]) normalized to cell 
density (in OD600 units) for small molecules tested in duplicate in an initial screen. 
Red dots represent DMSO controls; blue dots are small molecules tested. 
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RFU/OD and Z score ~0 for OD) and were selected for secondary cell-based 
screening. Compounds that produced induction were not pursued further. 
The secondary screening data obtained from the opuCA-gus reporter fusion 
strain (as described above) in the presence of 6 five-fold dilutions of the initial 
concentration (e.g. starting from a 64uM final concentration, 8009-2163 was diluted 1 
to 5 six times) of each of the 41 compounds, was used to calculate preliminary IC50 
values (i.e., concentration that inhibits 50% of σB activity).  14 compounds inhibited 
σB activity at concentrations lower than initially tested in the primary screen.  Based 
on drug developability criteria (58) and cytotoxicity information in ChemBank 
(chembank.broad.harvard.edu), poor drug candidates were eliminated, leaving three 
promising compounds that inhibited L. monocytogenes σB.  One particularly effective 
lead compound, 8009-2163 (IC50= ~15µM), was not commercially available, thus an 
analog of this compound (T0513-8332) was utilized (Figure 4.2).  T0513-8332 (2-
Phenyl-ethenesulfonic acid (4-fluoro-phenyl) amide), hereafter designated sigmastatin, 
has fluorine substituted for the hydrogen in the original compound.  While 8009-2163 
shows minimal evidence for cytotoxicity, based on cytotoxicity data in ChemBank, 
sigmastatin shows no evidence for cytotoxicity (chembank.broad.harvard.edu).  
 
Identification of σB binders using small-molecule microarrays (SMM) 
The ability of various small molecules to bind to σB was assessed using a SMM 
screen with His-tagged σB.  Using replicate Z-scores in Spotfire analytics, 19 high 
scoring σB ligands were identified (see Appendix Figure AF.1 for representative 
scatterplot). This included 10 compounds from the diversity oriented (DIV06) library 
and 9 from the natural products and commercial compound (NPC1) library. Several 
compounds were eliminated because of promiscuity (n=5), non-specific binding (n=5),  
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Figure 4.2: Structure of sigmastatin. Chemical structure of σB inhibitor sigmastatin 
(2-Phenyl-ethenesulfonic acid (4-fluoro-phenyl) amide). 
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or because they were not commercially available (n=6). Three purchasable ligands fit 
our criteria of lacking promiscuity and non-specificity, but subsequent assays showed 
they were not effective at inhibiting σB activity.  Several other compounds were tested 
but these compounds did not affect σB -dependent transcription in phenotypic and 
genotypic assays.  Therefore, while these compounds may bind σB, they do not inhibit 
σB activity. Though not among the top 19 binding compounds, sigmastatin was within 
the top 10% of the strongest σB ligands, suggesting the possibility of a direct 
interaction. These SMM data provide initial evidence that sigmastatin may inhibit σB 
activity by interacting with σB 
 
Multiple lines of evidence support σB activity inhibition by sigmastatin. 
To determine the phenotypic effects of sigmastatin at various concentrations, we 
qualitatively assessed its effect on the activity of bile salt hydrolase, which is the 
product of the σB-dependent bsh and required for survival in vivo (98).  L. 
monocytogenes treated with sigmastatin at concentrations of 96µM and 193 µM 
showed no BSH activity (Figure 4.3), although L. monocytogenes growth on BHI did 
not appear to be affected.  At 290µM of sigmastatin, L. monocytogenes produced no 
BSH activity and showed complete growth inhibition on BHI (Figure 4.3).  
To quantitatively assess the affects of σB –driven transcription, quantitative reverse 
transcriptase PCR (qRT-PCR) was used on mRNA from L. monocytogenes that had 
been exposed to σB inducing conditions (i.e., 0.3M NaCl for 10 min) in the presence or 
absence of various concentrations of sigmastatin.  Based on qRT-PCR experiments, 
there was a ~40-fold reduction in transcript levels for both σB -dependent genes 
opuCA and gadA following treatment with 64 µM of sigmastatin relative to transcript 
levels in cells that were not treated with sigmastatin (Figure 4.4a & 4.4b; p<0.05, 
GLM Tukey).  Concentration-dependent assessment of the effect of sigmastatin on 
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Figure 4.3: Phenotypic agar assay for σB-dependent BSH activity in the presence 
of sigmastatin at various concentrations. Left panel shows L. monocytogenes 
spotted on BHI agar, indicating growth, and the right panel shows L. monocytogenes 
spotted on MRS agar, indicating Bile Salt Hydrolase activity. Each well for both agars 
contains various concentrations of sigmastatin, from bottom to top: no treatment, 
96µM, 193µM, 290µM. L. monocytogenes grew on wells of BHI agar containing no 
treatment, 96µM and 193µM of sigmastatin, while little growth occurred at 290µM. L. 
monocytogenes deconjugated bile salts on MRS containing no sigmastatin, however, 
BSH was inhibited in all wells containing sigmastatin. 
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(a) 
 
(b) 
 
Figure 4.4. qRT-PCR graphs illustrating σB-dependent opuCA and gadA 
transcription. qRT-PCR graphs illustrating normalized log transformed (a) opuCA 
and (b) gadA transcription in L. monocytogenes 10403S and ∆sigB strains treated with 
0.3M NaCl, with or without sigmastatin at various concentrations for 10 min. Values 
represent mean log normalized transcript levels from at least three independent RNA 
collections.   
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transcription showed that transcript levels of opuCA in salt-treated 10403S cells, 
concurrently treated with sigmastatin (ranging from 8µM to 128µM), produced 
transcript levels which were equivalent to those seen in the ∆sigB strain (p>0.05). At 
4µM, sigmastatin significantly reduced transcription of opuCA (p<0.05), however, not 
to levels equivalent to ∆sigB strain (data not shown).  Using Sigmaplot and log-
normalized transcript levels of opuCA, the concentration at which half the maximal 
inhibition (IC50) occurred was determined to be 3.5µM. Importantly, absolute 
transcript levels for the housekeeping genes rpoB and gap were similar for 10403S 
with and without exposure to sigmastatin, indicating that this small molecule 
specifically inhibits transcription of σB-dependent genes and does not affect 
housekeeping functions. As a consequence of treatment with sigmastatin, there was no 
further σB directed activity in a treated strain as compared to a ∆sigB strain. 
Sigmastatin is effective in that there is not a reduction but elimination of σB-dependent 
activity at levels as low as 8µM. 
 
L. monocytogenes whole genome microarray identified 208 genes downregulated 
by treatment with sigmastatin; 156 of these genes are regulated by σB.   
To further characterize the ability of sigmastatin to specifically inhibit σB, 
transcriptional profiling was performed using a L. monocytogenes whole-genome 
microarray. Microarray profiling was performed on four independent RNA collections 
from log-phase salt stressed L. monocytogenes exposed to either 64 µM sigmastatin or 
to DMSO alone (the solvent used for sigmastatin).  Analysis of microarray data (using 
LIMMA package for R) showed that 208 genes were downregulated and 32 genes 
were upregulated as a result of treatment with sigmastatin (adj. p<0.05 and FC≥2).  
156 of the 208 sigmastatin-downregulated genes are positively regulated by σB and 7 
of the 32 sigmastatin-upregulated genes are negatively regulated by σB, based on  
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previous microarray analysis in 10403S and EGD-e, RNA seq and HMM (Table 4.2, 
Table 4.3 and 4.4) (35, 45, 71, 72, 77, 98). There are 115 sigmastatin-downregulated 
genes positively regulated by σB in both the L. monocytogenes strains 10403S and 
EGD-e (35, 45, 71, 72, 77, 98). An additional 21 genes are positively regulated by σB 
specifically in the L. monocytogenes strain 10403S (45, 71, 72, 77) and another 20 are 
positively regulated by σB specifically in the L. monocytogenes strain EGD-e (35, 98). 
Interestingly, sigmastatin inhibited >90% of genes with an HMM identified σB-
dependent promoter. 
Of the 208 sigmastatin-downregulated genes, 126 were found to be positively 
regulated by σB during infection in the murine intestine (98), including 17 σB-
dependent genes specific to the intestine (Table 4.4 and 4.5).  Among these 17 genes, 
9 genes were of unknown or hypothetical function. Three genes lmo0584, lmo0648, 
lmo0650 were similar to membrane proteins, while lmo0649 and lmo0651 were 
similar to transcriptional regulators. One gene, lmo1992 was similar to alpha-
acetolactate decarboxylase, another, lmo1789, was similar to Nad(P)h Oxidoreductase 
chain B and a third, lmo0406, was similar to B. subtilis YyaH protein.  
Results from Gene Set Enrichment Analysis (GSEA, Broad Institute, 
Cambridge, MA) further supported that sigmastatin extensively inhibited the σB 
regulon, as the known σB -regulated genes were significantly enriched among 
sigmastatin-downregulated genes (False discovery rate (FDR) q<0.0001). Note that in 
GSEA gene sets are considered significant at an FDR q<0.25. To assess the effects of 
sigmastatin on the function of other alternative sigma factors, transcript levels for 
genes in the σH and σL regulons were assessed.  14 of the 30 genes identified as σH–
dependent (p<0.05, FC≥2) were significantly and differentially downregulated by 
sigmastatin (adj. p<0.05, FC≥2), however, 12 of those 14 genes are also σB -
dependent. GSEA showed that the σH-only regulon (comprised of genes that are only  
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Table 4.2: Number of genes differentially expression as a result of treatment with 
sigmastatin and correlation to σB regulation 
 208 genes downregulated by 
sigmastatin 
32 genes upregulated by 
sigmastatin 
Positively σB regulated 156 a 2  
Negatively σB regulated 6 b  7 
σB-dependent promoters 86 c  0 
a 156 genes includes 4 genes positively regulated by σB under some conditions, but negatively regulated 
by σB under other conditions. See supplemental tables 1 and 3. 
b 6 genes includes 4 genes negatively regulated by σB under some conditions, but positively regulated 
by σB under other conditions. See supplemental tables 2 and 3. 
c σB-dependent promoters as determined by in silico analysis using Hidden Markov Model (71). 
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Table 4.3. Comparison of genes downregulated by T0513 and σB dependent 
genes previously identified in 10403S and EGD-e  
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Gene 
name 
Sigma-
statin 
FCa 
Sigma-
statin adj. p 
value  
σB salt 
FCb 
σB salt 
adj. p 
valueb 
σB 
stationary 
FCb 
σB 
stationary 
ad. p 
valueb 
σB 
dependent 
promoterc 
σB -
dependent 
in other 
studiesd 
lmo0019 -21.3 0.0000 5.1 0.0004 3.5 0.0010  +  + 
lmo0025 -10.3 0.0000 1.2 0.0354 1.2 0.1720 .  
lmo0026 -4.4 0.0000 1.1 0.4304 1.0 0.8397 .  
lmo0036 -4.9 0.0000 1.6 0.0062 1.1 0.7999 .  
lmo0038 -3.8 0.0000 1.5 0.0031 1.1 0.3917 .  
lmo0039 -5.1 0.0000 1.6 0.0103 1.1 0.7672 .  
lmo0043 -26.0 0.0000 4.0 0.0001 3.5 0.0003  +  + 
lmo0090 -2.4 0.0000 1.3 0.0262 1.0 0.8873 .  
lmo0105 -2.2 0.0023 1.0 0.7338 1.0 0.7668 .  
lmo0129 -2.4 0.0000 1.1 0.6574 1.1 0.8473 .  
lmo0133 -4.5 0.0000 2.4 0.0070 1.2 0.4341  +  + 
lmo0134 -29.6 0.0000 6.7 0.0001 6.2 0.0001  +  + 
lmo0169 -11.7 0.0000 2.8 0.0044 2.1 0.0025  +  + 
lmo0170 -12.5 0.0000 4.0 0.0003 1.9 0.1905  +  + 
lmo0232 -2.1 0.0000 2.5 0.0010 0.8 0.4050 .  
lmo0274 -3.5 0.0000 1.1 0.8128 1.2 0.2321  +  + 
lmo0291 -5.2 0.0000 2.0 0.0004 2.1 0.0006 .  + 
lmo0321 -29.0 0.0000 3.0 0.0006 4.3 0.0000  +  + 
lmo0326 -2.1 0.0019 1.0 0.9104 1.0 0.9343 .  
lmo0335 -3.2 0.0000 1.3 0.0081 1.0 0.9526 .  
lmo0336 -3.6 0.0000 1.2 0.3953 1.1 0.8672 .  
lmo0337 -3.0 0.0000 1.3 0.0252 1.1 0.7318 .  
lmo0339 -3.9 0.0000 1.4 0.0269 1.1 0.6423 .  
lmo0405 -11.3 0.0000 2.0 0.0012 2.1 0.0010  +  + 
lmo0406 -5.0 0.0000 1.5 0.0028 1.6 0.0158 .  + 
lmo0407 -2.2 0.0000 1.3 0.1307 1.5 0.0029 .  + 
lmo0408 -2.6 0.0000 1.2 0.1957 1.5 0.0074 .  + 
lmo0433 -31.3 0.0000 2.0 0.0135 1.3 0.0608  +  + 
lmo0434 -24.6 0.0000 2.0 0.0124 1.4 0.0085  +  + 
lmo0439 -14.4 0.0000 1.7 0.0073 1.4 0.1021  +  + 
lmo0445 -16.1 0.0000 2.5 0.0006 3.0 0.0004 .  + 
lmo0479 -7.7 0.0000 1.3 0.0362 1.4 0.0852 .  
lmo0515 -19.9 0.0000 2.6 0.0020 2.1 0.0116  +  + 
lmo0524 -4.5 0.0000 1.5 0.4178 1.9 0.0007 .  + 
lmo0528 -2.0 0.0000 1.0 0.9412 1.2 0.1568 .  
lmo0529 -2.4 0.0000 1.1 0.3424 1.1 0.3850 .  + 
lmo0530 -2.3 0.0000 0.9 0.8041 1.1 0.6027 .  
lmo0531 -2.4 0.0000 1.1 0.7082 1.1 0.8592 .  
lmo0539 -21.6 0.0000 18.8 0.0001 13.7 0.0000  +  + 
lmo0554 -28.5 0.0000 4.0 0.0004 4.4 0.0001  +  + 
lmo0555 -11.2 0.0000 2.8 0.0032 4.1 0.0003  +  + 
lmo0579 -3.5 0.0000 1.5 0.0225 1.5 0.0035 .  + 
lmo0580 -3.2 0.0000 2.2 0.0002 1.6 0.0219 .  + 
lmo0584 -3.0 0.0000 1.2 0.1896 1.4 0.0342 .  + 
lmo0589 -7.6 0.0000 3.9 0.0002 1.8 0.0018 .  
lmo0590 -8.2 0.0000 4.1 0.0002 1.9 0.0047 .  + 
lmo0591 -10.2 0.0000 5.4 0.0008 1.7 0.0006 .  + 
lmo0593 -3.0 0.0000 1.5 0.0092 4.3 0.0001  +  + 
lmo0596 -86.4 0.0000 17.7 0.0001 12.3 0.0002  +  + 
lmo0598 -2.8 0.0005 1.0 0.8496 1.1 0.7203   
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lmo0602 -21.9 0.0000 5.5 0.0003 3.0 0.0007  +  + 
lmo0606 -8.9 0.0000 1.5 0.0045 1.2 0.1320 .  
lmo0607 -12.6 0.0000 2.1 0.0011 1.1 0.4354 .  
lmo0608 -13.5 0.0000 3.3 0.0001 0.8 0.1862 .  
lmo0610 -20.6 0.0000 1.6 0.0015 2.3 0.0006  +  + 
lmo0626 -2.3 0.0000 1.3 0.0421 1.2 0.2172 .  + 
lmo0628 -27.1 0.0000 2.2 0.0018 3.8 0.0002  +  + 
lmo0629 -6.2 0.0000 1.7 0.0126 2.3 0.0002  +  + 
lmo0642 -3.7 0.0000 1.1 0.5652 1.5 0.4353 .  
lmo0647 -7.8 0.0000 4.8 0.0005 3.6 0.0029 .  + 
lmo0648 -4.2 0.0000 1.6 0.1804 1.6 0.0031 .  + 
lmo0649 -3.8 0.0000 1.3 0.1622 1.4 0.0076 .  + 
lmo0650 -3.4 0.0000 1.3 0.0413 1.2 0.1961 .  + 
lmo0651 -2.1 0.0000 1.4 0.0385 1.0 0.9298 .  + 
lmo0653 -2.2 0.0000 2.3 0.0025 1.2 0.5446 .  
lmo0654 -16.3 0.0000 2.2 0.0004 2.1 0.0027  +  + 
lmo0655 -12.7 0.0000 2.5 0.0006 2.0 0.0004  +  + 
lmo0669 -71.3 0.0000 34.4 0.0001 34.4 0.0000  +  + 
lmo0670 -51.4 0.0000 12.8 0.0001 8.3 0.0001  +  + 
lmo0671 -2.0 0.0000 1.1 0.7433 1.0 0.9100 .  
lmo0722 -22.8 0.0000 4.5 0.0005 2.3 0.0074  +  + 
lmo0759 -3.6 0.0000 1.3 0.0383 1.3 0.0138 .  + 
lmo0760 -3.6 0.0000 1.3 0.0322 1.4 0.0076 .  + 
lmo0761 -3.3 0.0000 1.2 0.6426 1.0 0.9955 .  + 
lmo0781 -14.8 0.0000 2.9 0.3955 3.3 0.0000  +  + 
lmo0782 -22.9 0.0000 10.3 0.0001 12.6 0.0000  +  + 
lmo0783 -26.9 0.0000 8.9 0.0001 10.8 0.0000  +  + 
lmo0784 -24.0 0.0000 8.5 0.0001 10.2 0.0000  +  + 
lmo0794 -28.1 0.0000 2.3 0.0016 5.5 0.0002  +  + 
lmo0796 -16.1 0.0000 6.7 0.0001 3.7 0.0000  +  + 
lmo0819 -4.7 0.0000 1.6 0.0062 1.4 0.0267 .  + 
lmo0820 -2.7 0.0000 1.0 0.8773 1.1 0.8282 .  
lmo0821 -2.2 0.0000 1.3 0.0085 1.4 0.0105 .  
lmo0869 -3.0 0.0000 1.2 0.0386 1.5 0.0282 .  + 
lmo0880 -70.7 0.0000 12.3 0.0001 13.0 0.0002  +  + 
lmo0893 -6.6 0.0000 2.2 0.0005 1.5 0.0071  +  + 
lmo0894 -6.9 0.0000 2.4 0.0011 1.3 0.0473  +  + 
lmo0895 -6.7 0.0000 5.1 0.0001 2.1 0.0004  +  + 
lmo0896 -6.9 0.0000 4.2 0.0003 2.2 0.0003  +  + 
lmo0904 -2.7 0.0000 1.2 0.0835 1.5 0.0065 .  
lmo0911 -5.7 0.0000 3.8 0.0004 2.7 0.0006  +  + 
lmo0913 -80.0 0.0000 9.7 0.0002 5.8 0.0001  +  + 
lmo0915 -6.6 0.0000 1.2 0.3224 0.8 0.1093 .  
lmo0937 -4.7 0.0000 3.3 0.0090 3.8 0.0006  +  + 
lmo0953 -20.8 0.0000 3.0 0.0007 3.0 0.0001  +  + 
lmo0956 -5.0 0.0000 2.7 0.0001 2.3 0.0000 .  + 
lmo0957 -3.2 0.0000 2.2 0.0003 1.7 0.0010 .  + 
lmo0958 -2.4 0.0000 2.0 0.0002 1.5 0.0634 .  + 
lmo0994 -39.8 0.0000 7.6 0.0003 7.3 0.0000  +  + 
lmo0995 -35.6 0.0000 3.9 0.0003 2.8 0.0005 .  + 
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lmo1018 -2.1 0.0000 0.9 0.1656 1.3 0.0631 .  
lmo1026 -2.0 0.0000 1.8 0.2523 0.8 0.0637 .  
lmo1027 -2.0 0.0000 2.5 0.0011 0.8 0.1705 .  
lmo1139 -2.1 0.0000 0.8 0.3268 1.2 0.1902 .  + 
lmo1140 -10.8 0.0000 4.5 0.0001 5.9 0.0000 .  + 
lmo1241 -22.7 0.0000 2.3 0.0017 2.6 0.0001  +  + 
lmo1251 -3.2 0.0000 1.1 0.7622 1.0 0.8895 .  
lmo1261 -12.0 0.0000 1.9 0.0003 1.8 0.0195 .  + 
lmo1266 -2.0 0.0000 0.5 0.0011 1.3 0.2658 .  
lmo1293 -4.1 0.0000 2.2 0.0003 0.3 0.0018 .  +/- 
lmo1295 -4.0 0.0000 2.5 0.0003 3.9 0.0000  +  + 
lmo1340 -2.2 0.0000 1.0 0.8446 1.1 0.6705 .  + 
lmo1375 -16.5 0.0000 2.9 0.0006 3.4 0.0003 .  + 
lmo1421 -9.0 0.0000 3.1 0.0002 1.5 0.0410  +  + 
lmo1422 -8.2 0.0000 2.9 0.0012 1.3 0.2771 .  + 
lmo1425 -26.7 0.0000 7.0 0.0003 1.8 0.0027  +  + 
lmo1426 -15.8 0.0000 2.7 0.0028 1.0 0.9582  +  + 
lmo1427 -27.1 0.0000 3.0 0.0004 2.0 0.0011  +  + 
lmo1428 -49.9 0.0000 10.1 0.0004 2.9 0.0000  +  + 
lmo1432 -2.3 0.0000 1.8 0.0019 2.1 0.0002 .  + 
lmo1433 -35.6 0.0000 2.7 0.0014 2.6 0.0004  +  + 
lmo1452 -3.2 0.0000 1.0 0.8390 1.0 0.8428 .  
lmo1453 -3.2 0.0000 1.1 0.4123 1.2 0.1549 .  + 
lmo1454 -3.7 0.0000 1.1 0.6346 1.0 0.8592 .  + 
lmo1526 -9.1 0.0000 2.6 0.0003 1.9 0.0459  +  + 
lmo1538 -3.2 0.0000 1.4 0.2131 0.3 0.0005 .  +/- 
lmo1539 -3.7 0.0000 1.8 0.0453 0.2 0.0001 .  +/- 
lmo1580 -4.1 0.0000 1.9 0.0039 2.6 0.0000 .  + 
lmo1601 -3.3 0.0000 2.5 0.0004 4.2 0.0000  +  + 
lmo1602 -2.7 0.0001 3.6 0.0001 5.1 0.0000  +  + 
lmo1605 -2.0 0.0000 1.3 0.0478 1.7 0.0458 .  + 
lmo1606 -2.9 0.0000 1.2 0.1152 2.8 0.0005 .  + 
lmo1666 -6.2 0.0000 1.8 0.0125 1.5 0.0152 .  
lmo1694 -28.9 0.0000 3.4 0.0002 2.6 0.0002  +  + 
lmo1698 -2.9 0.0000 1.5 0.0862 2.0 0.0004  +  + 
lmo1704 -2.3 0.0000 1.4 0.0110 1.8 0.0005 .  + 
lmo1789 -3.7 0.0000 1.3 0.0341 1.4 0.0096 .  + 
lmo1790 -2.0 0.0000 1.8 0.0315 1.5 0.0199 .  + 
lmo1830 -8.8 0.0000 2.0 0.0078 2.4 0.0007  +  + 
lmo1883 -5.4 0.0000 2.5 0.0013 12.0 0.0000  +  + 
lmo1912 -2.4 0.0000 1.0 0.9728 1.1 0.4354 .  
lmo1913 -2.2 0.0000 1.0 0.8086 0.9 0.6772 .  
lmo1929 -2.0 0.0000 0.9 0.5359 1.5 0.0495 .  + 
lmo1930 -2.1 0.0000 1.2 0.1519 1.5 0.0341 .  
lmo1992 -3.0 0.0000 1.9 0.0013 0.6 0.2004 .  +/- 
lmo2006 -2.1 0.0000 0.7 0.0171 0.5 0.0036 .  - 
lmo2066 -2.2 0.0000 1.2 0.1757 0.9 0.6796 .  - 
lmo2067 -37.5 0.0000 3.2 0.0004 4.4 0.0004  +  + 
lmo2085 -21.1 0.0000 5.0 0.0002 11.1 0.0000  +  + 
lmo2092 -2.4 0.0000 1.2 0.1013 1.0 0.8592 .  
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Table 4.3 (Continued) 
Gene 
name 
Sigma-
statin 
FCa 
Sigma-
statin adj. p 
value  
σB salt 
FCb 
σB salt 
adj. p 
valueb 
σB 
stationary 
FCb 
σB 
stationary 
ad. p 
valueb 
σB 
dependent 
promoterc 
σB -
dependent 
in other 
studiesd 
lmo2130 -3.8 0.0000 1.3 0.0643 2.5 0.0892 .  + 
lmo2131 -3.0 0.0000 1.1 0.2793 1.0 0.9253 .  
lmo2132 -9.4 0.0000 1.8 0.0133 3.8 0.0005  +  + 
lmo2157 -40.4 0.0000 13.9 0.0001 11.6 0.0000  +  + 
lmo2158 -22.9 0.0000 17.8 0.0429 15.6 0.0000  +  + 
lmo2173 -2.6 0.0000 1.2 0.0597 0.9 0.3349 .  
lmo2174 -6.7 0.0000 1.2 0.0785 1.2 0.1434 .  + 
lmo2191 -2.5 0.0000 3.5 0.0001 2.7 0.0001 .  + 
lmo2205 -3.8 0.0000 4.3 0.0001 2.2 0.0020 .  + 
lmo2213 -55.2 0.0000 14.1 0.0001 11.6 0.0000  +  + 
lmo2230 -54.7 0.0000 33.9 0.0001 21.8 0.0001  +  + 
lmo2231 -21.0 0.0000 2.6 0.0106 2.3 0.0004 .  + 
lmo2232 -2.6 0.0000 4.9 0.0025 1.6 0.0104 .  
lmo2269 -11.9 0.0000 2.5 0.0092 5.7 0.0000  +  + 
lmo2281 -2.5 0.0000 1.1 0.1657 1.2 0.1188 .  
lmo2283 -2.2 0.0000 1.1 0.3049 1.0 0.8299 .  
lmo2356 -3.8 0.0000 1.2 0.0938 1.1 0.8214 .  
lmo2357 -2.3 0.0000 1.3 0.1550 1.3 0.0589 .  
lmo2358 -3.0 0.0000 1.2 0.0700 1.1 0.5653 .  
lmo2375 -2.1 0.0000 0.8 0.1706 1.1 0.2510 .  
lmo2386 -4.4 0.0000 2.3 0.0017 1.6 0.0012 .  + 
lmo2387 -30.1 0.0000 1.2 0.2264 2.1 0.0019  +  + 
lmo2391 -26.4 0.0000 5.7 0.0003 7.5 0.0000  +  + 
lmo2398 -8.7 0.0000 7.0 0.0001 2.3 0.0006 .  + 
lmo2399 -4.3 0.0000 1.9 0.0136 1.3 0.1394 .  + 
lmo2400 -4.4 0.0000 1.4 0.0179 1.3 0.1273 .  
lmo2434 -21.7 0.0000 4.1 0.0023 3.4 0.0001  +  + 
lmo2436 -2.0 0.0000 1.1 0.4100 1.3 0.0918 .  
lmo2454 -3.3 0.0000 1.6 0.0377 4.4 0.0000  +  + 
lmo2463 -13.0 0.0000 1.7 0.0029 2.3 0.0001  +  + 
lmo2471 -2.1 0.0000 2.2 0.0001 1.0 0.9515 .  
lmo2484 -2.2 0.0008 6.2 0.0002 5.2 0.0000 .  + 
lmo2485 -2.2 0.0004 4.4 0.0002 3.7 0.0000 .  + 
lmo2494 -12.4 0.0000 2.4 0.0006 2.7 0.0001 .  + 
lmo2570 -3.5 0.0010 3.1 0.0016 1.9 0.0019  +  + 
lmo2571 -32.9 0.0000 6.2 0.0001 4.0 0.0000  +  + 
lmo2572 -27.3 0.0000 4.4 0.0005 3.5 0.0000  +  + 
lmo2573 -36.1 0.0000 4.9 0.0004 4.0 0.0000  +  + 
lmo2602 -10.8 0.0000 1.4 0.0393 2.2 0.0004  +  + 
lmo2603 -5.6 0.0000 2.9 0.0026 3.8 0.0004  +  + 
lmo2670 -6.0 0.0000 2.3 0.0031 1.9 0.0015  +  + 
lmo2671 -7.9 0.0000 2.8 0.0002 2.8 0.0000  +  + 
lmo2672 -9.5 0.0000 1.9 0.0137 1.7 0.0738  +  + 
lmo2673 -46.3 0.0000 7.4 0.0003 13.2 0.0000  +  + 
lmo2674 -3.5 0.0000 1.8 0.0033 2.7 0.0000  +  + 
lmo2685 -2.2 0.0000 0.9 0.4081 1.2 0.1862 .  
lmo2695 -20.8 0.0000 7.0 0.0001 1.3 0.2896 .  + 
lmo2696 -20.6 0.0000 6.5 0.0001 1.5 0.0469 .  + 
lmo2697 -6.6 0.0000 1.9 0.0146 1.9 0.0147 .  + 
lmo2724 -12.6 0.0000 3.7 0.0010 1.8 0.0033  +  + 
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Table 4.3 (Continued) 
Gene 
name 
Sigma-
statin 
FCa 
Sigma-
statin adj. p 
value  
σB salt 
FCb 
σB salt 
adj. p 
valueb 
σB 
stationary 
FCb 
σB 
stationary 
ad. p 
valueb 
σB 
dependent 
promoterc 
σB -
dependent 
in other 
studiesd 
lmo2733 -3.2 0.0000 1.0 0.8786 1.1 0.2455  +  + 
lmo2734 -2.1 0.0007 1.2 0.0718 1.2 0.2295 .  
lmo2735 -2.0 0.0023 1.1 0.2246 1.2 0.1684 .  
lmo2739 -5.0 0.0000 2.2 0.0007 1.3 0.0715 .  
lmo2740 -4.6 0.0000 1.9 0.0008 1.2 0.1449 .  
lmo2741 -4.6 0.0000 1.8 0.0057 1.2 0.0869 .  
lmo2748 -67.5 0.0000 15.6 0.0002 8.9 0.0000  +  + 
LMOinlD -7.4 0.0000 1.2 0.2104 1.1 0.6806  +  + 
a FC indicates fold change 
b This work was reported in Raengpradub et al., 2008. 
c σB -dependent promoter was determined by HMM in Oliver et al., 2009. 
d Other studies: Hain et al., 2008, Kazmierczak  et al., 2003, Oliver et al., 2009, Ollinger et al., 2009, 
Toledo-Arana et al., 2009.  
Items listed in bold are significantly and differentially expressed; “+” indicates positively regulated in 
other studies and “-” indicates negatively regulated in other studies. “+/-” indicates positively and 
negatively regulated in other studies 
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Table 4.4. Comparison of genes upregulated by sigmastatin and σB dependent 
genes previously identified in 10403S and EGD-e 
 
Gene 
name 
Sigma
-statin 
FCa 
Sigma- 
statin 
adj. p 
value 
σB 
salt 
FCb 
σB salt 
adj. p 
valueb 
σB 
stationary 
FCb 
σB 
stationary 
adj. p 
valueb 
σB 
dependent 
promoterc 
σB 
dependent 
in other 
studiesd 
lmo0194 2.1 0.0000 1.0 0.7701 0.9 0.5751 .  
lmo0195 2.5 0.0001 0.9 0.1975 0.8 0.1647 .  
lmo0560 2.4 0.0000 0.7 0.0872 0.4 0.0000 .  
lmo0604 2.6 0.0000 1.0 0.8953 0.9 0.1543 .  
lmo0678 2.3 0.0008 0.9 0.5684 0.9 0.5568 .  
lmo0679 4.0 0.0000 0.5 0.0008 0.7 0.0897 .  
lmo0680 4.7 0.0000 0.8 0.0399 0.7 0.0432 .  
lmo0681 3.3 0.0000 0.6 0.0019 0.9 0.4655 .  
lmo0685 2.1 0.0002 0.6 0.0315 0.7 0.0179 .  
lmo0686 2.0 0.0000 0.7 0.3102 1.0 0.9515 .  
lmo0955 2.0 0.0001 0.9 0.6439 1.2 0.1147 .  
lmo0971 2.1 0.0000 0.5 0.0015 0.8 0.1608 .  
lmo0973 2.2 0.0000 0.7 0.0121 0.9 0.8428 .  
lmo0974 2.6 0.0000 0.4 0.0010 1.0 0.9231 .  
lmo1440 2.0 0.0000 0.8 0.1900 1.3 0.2283 . - 
lmo1518 2.7 0.0000 0.6 0.0004 1.0 0.7859 .  
lmo1637 2.2 0.0000 1.1 0.7880 1.3 0.1219 . + 
lmo1699 4.7 0.0000 0.2 0.0001 0.8 0.3118 .  
lmo1700 5.7 0.0000 0.2 0.0001 0.9 0.2974 .  
lmo1919 2.7 0.0000 1.6 0.0683 1.0 0.9092 .  
lmo2114 3.7 0.0000 0.3 0.0001 1.0 0.9829 .  
lmo2115 3.7 0.0000 0.7 0.0419 0.9 0.7332 .  
lmo2150 2.9 0.0000 0.5 0.0011 0.8 0.1888 .  
lmo2156 3.0 0.0000 0.8 0.1686 1.0 0.9706 .  
lmo2177 3.0 0.0000 1.2 0.0860 0.9 0.2393 .  
lmo2219 2.3 0.0000 0.5 0.0007 1.0 0.7667 .  
lmo2439 2.7 0.0000 0.7 0.0465 1.2 0.5422 .  
lmo2567 2.4 0.0000 1.0 0.9800 1.1 0.3660 .  
lmo2568 2.0 0.0000 1.0 0.9544 1.1 0.8473 . + 
lmo2687 3.5 0.0000 1.1 0.6130 0.9 0.4532 .  
lmo2688 2.7 0.0000 1.4 0.1067 1.0 0.8594 .  
lmo2689 3.0 0.0000 0.9 0.7075 1.0 0.8351 .  
a FC indicates fold change 
b This work was reported in Raengpradub et al., 2008. 
c σB -dependent promoter was determined by HMM in Oliver et al., 2009. 
d Other studies: Hain et al., 2008, Kazmierczak  et al., 2003, Ollinger et al., 2009, Toledo-Arana et al., 
2009.  
Items listed in bold are significantly and differentially expressed; “+” indicates positively regulated in 
other studies and “-” indicates negatively regulated in other studies. “+/-” indicates positively and 
negatively regulated in other studies 
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Table 4.5: Positively regulated σB dependent genes previously identified in L. 
monocytogenes 10403S and EGD-e 
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regulated by σH and not co-regulated by σB) was not significantly enriched as a result 
of sigmastatin treatment (FDR q=0.472). Furthermore, GSEA of the σL regulon 
showed that it was not significantly enriched as a result of treatment with sigmastatin 
(FDR q=0.836). GSEA was used to determine the biological role category distribution 
of genes that were differentially affected by sigmastatin. Gene sets representing 
biological functions including Cellular Processes: Adaptations to Atypical Conditions 
and Energy Metabolism (other) were enriched amongst sigmastatin-downregulated 
genes (FDR q=0.060 and q=0.201, respectively). The Cellular Processes: Pathogenesis 
gene set was also overrepresented amongst sigmastatin-downregulated genes, although 
just short of significant (FDR q=0.251). Conversely, biological functions such as 
Cellular Processes: Chemotaxis and Motility, Protein Fate: Protein Folding and 
Stabilization, and Amino Acid Biosynthesis: Histidine Family were enriched among 
sigmastatin-upregulated genes (FDR q<0.0001, q=0.008, q=0.031, respectively). 
GSEA was also performed on the subset of genes that were downregulated by 
sigmastatin but not σB regulated, and it was determined that no role category or 
regulator, amongst those tested, was enriched in this group of genes (FDR q>0.25).   
Genes that showed significantly reduced transcript levels in sigmastatin treated 
cells include the virulence and in vivo viability-associated genes inlD, bilEAB, bsh, 
hfq, clpC, opuC, and gadA as well as known virulence genes inlA, inlB. In fact, the 
regulon of PrfA, the pleiotropic virulence gene regulator, was significantly enriched 
among the data set, as three genes inlA, inlB, plcA, of its small regulon were enriched 
among sigmastatin downregulated genes (FDR q=0.095). Both inlA and inlB were 
significantly downregulated by sigmastatin, however, plcA, encoding phospholipase 
C, was downregulated (adj. p<0.05), but with a fold change of 1.57 it did not meet our 
cut off criteria of ≥ 2 fold differential transcription. Interestingly, nineteen genes of the 
Group III PrfA-regulated genes co-controlled by σB are both upregulated in the mouse 
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spleen (14) and inhibited by sigmastatin. This data set includes three genes 
differentially regulated in the host and identified as potential virulence factors (14), 
such as lmo1601 (general stress protein), lmo1602 (unknown protein), and lmo2157 
(SepA, a metalloprotease in S. epidermis (53) and upregulated in L. monocytogenes 
during intracellular infection (16)). A fourth gene inhibited by sigmastatin, also 
identified as a potential virulence factor by Camejo et al., 2009 (14), is lmo0915, a 
component of a phosphotransferase system whose regulation has yet to be attributed to 
any factor. Additionally, sigmastatin also downregulated lmo0937, a gene upregulated 
in the mouse spleen at 48 hr post-infection and found in the Group III PrfA regulated 
genes not thought to be controlled by σB (14). 
Operons identified by Raengpradub et al., 2008 (77) as σB –regulated were also 
significantly differentially transcribed after treatment with sigmastatin, these include 
inlAB (mediates entry into non-professional phagocytes(17)), opuCABCD (involved in 
compatible solute transport), and the 2 gene operon, lmo1699 and lmo1700 (involved 
in methyl accepting chemotaxis) (Figure 4.5).   The autoregulated sigB operon 
consisting of lmo0893-0896 (rsbV, rsbW, sigB, rsbX) was downregulated, which 
likely contributed to further downregulation of the entire regulon.  Of note, regulators 
of σB, rsbX and upstream gene rsbU were recently found to be up regulated during 
infection in a mouse spleen (14).  
Several additional σB-dependent genes downregulated by sigmastatin were 
previously shown to be upregulated during intracellular infection (16) including 
lmo0232 (clpC), lmo0445 (transcriptional regulator), lmo0783 (part of an operon 
encoding manose phosphotransferase system components, each gene of which is 
downregulated by sigmastatin) and lmo2672 (also similar to a transcriptional 
regulator).  Furthermore, sigmastatin inhibited cell wall-associated genes, which are 
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Figure 4.5: σB-dependent operons affected by sigmastatin. According to 
transcriptional profiling of cells treated with sigmastatin, various genes in operons 
were significantly differentially expressed, including downregulated operons 
comprised of virulence genes and genes encoding compatible solute transporters. 
Expression of genes in a motility and chemotaxis operon was upregulated as a result 
of treatment. As our compound mimics a σB null status in the cell, genes that are 
positively regulated by σB will be downregulated by sigmastatin.  
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upregulated under intracellular conditions (16) and in the murine intestine (98), 
including inlA, inlD, lmo0610, lmo0880, lmo2085 (all of which contain LPXTG 
sorting motif for cell-wall anchoring) and inlB (with a GW domain for mediating 
binding to host ligands (60)). 
Three genes important to glycerol utilization and also required for intracellular 
listerial growth (43), which were downregulated by sigmastatin, are also regulated by 
σB either positively or negatively under various conditions.  Utilization of glycerol as a 
carbon source in intracellular environments (16) is required for intracellular survival 
(43).  Two of these glycerol utilization genes, lmo1538 (glycerol kinase) and lmo1539 
(glycerol uptake facilitator) are downregulated by sigmastatin and are negatively 
regulated by σB in stationary phase and salt stress conditions (77).  Interestingly, 
however, both genes were upregulated by σB in the intestine (98) and during 
intracellular replication (16). The third gene downregulated by sigmastatin, lmo1293, 
(glpD) a glycerol-3-phosphate dehydrogenase, was positively regulated by σB in salt 
(77), intracellularly (43) and in the gastrointestinal tract (98) but downregulated by σB 
in stationary phase (77). The σB regulon clearly differs depending on the condition and 
needs of the bacterial cell (45). In addition to our data, this is further supported by 
Camejo et al., who found that 40 σB dependent genes downregulated in stationary 
phase (35), were activated in vivo in the mouse spleen (14).  Furthermore, 
transcriptional profiling of L. monocytogenes in the murine intestine indicates three 
genes (lmo0642, lmo1251, and lmo1930) exhibited higher expression in the intestine 
in a WT strain but not ∆sigB strain (98). These three genes were also downregulated 
by sigmastatin.  It is likely that several of the genes inhibited by sigmastatin and not 
previously attributed to σB regulation under in vitro conditions, are σB-dependent but 
only under very specific conditions, such as those in the mouse intestine. To support 
this, Camejo et al. demonstrated that expression of genes in vitro is indeed lower than 
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expression of genes in vivo (14). Most importantly, however, it is clear that 
sigmastatin downregulates many genes that enable the bacterium to cause infection. 
 
A smaller proportion of genes upregulated by sigmastatin, as compared to genes 
downregulated by sigmastatin, are σB-dependent 
Of the 32 genes upregulated by sigmastatin, only 7 genes were negatively 
regulated by σB in both EGD-e and 10403S strains (35, 77).  The σB-dependent genes 
with known functions included an ABC transporter (lmo2114), D-alanine-activating 
enzyme (dltA), post-translocation chaperone (prsA), methyl-accepting chemotaxis 
protein (lmo1699-1700), and NADP glutamate dehydrogenase (lmo0560).  Though 
two genes, lmo2568 (of unknown function) and lmo1637 (similar to membrane 
protein), were upregulated by sigmastatin, they were also positively regulated by σB in 
the intestine (98) and during various growth phases (35), respectively. Among the non 
σB-dependent genes upregulated by sigmastatin, some were involved in ABC 
transport, motility and cell-division, but most had unknown functions (Table 4.4).  
As previously mentioned, genes ascribed to the motility and chemotaxis role 
category, were enriched among sigmastatin-upregulated genes according to GSEA. 
The large flagellar biosynthesis and motility operon (lmo0673-0718) contains 13 
recognized σB dependent genes (77).  Interspersed among these, are six sigmastatin-
upregulated genes, which have not been described previously as σB-dependent, 
including lmo0678, lmo0679, lmo0680, lmo0681, lmo0685, lmo0686.  Many 
additional motility genes in this operon were enriched among sigmastatin-upregulated 
genes (FDR q<0.0001), although they were not significantly and differentially 
expressed.  Because of the high number of motility genes affected by sigmastatin, 
GSEA was performed on the regulons of known chemotaxis and motility related 
regulators DegU, MogR and CodY.  This analysis also showed that the DegU operon 
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(as defined by Williams et al., 2005 (103)) was enriched in our gene set, among 
upregulated genes (FDR q<0.0001).  Although MogR, the transcriptional repressor of 
flagellum genes (34, 89), was shown to be σB-dependent (98), its regulon (89) was not 
significantly enriched among our microarray dataset (FDR q=0.257).  CodY, the 
transcriptional repressor of motility and chemotaxis in B. subtilis (64), also negatively 
regulates flagellar components in L. monocytogenes (5).  Therefore, the genes in the 
CodY regulon were examined and were found to be significantly enriched among 
upregulated genes as a result of treatment with sigmastatin (FDR q<0.0001).  
We surmise that several new genes, which were significantly and differentially 
expressed resulting from treatment with sigmastatin, may be σB dependent if they are 
part of an operon containing at least one σB dependent gene also affected by 
sigmastatin.  For example, previously only lmo0974 or dltA (the first gene in the 
operon important for modifying lipotechoic and wall techioc acid) was shown to be 
negatively regulated by σB.  However, in addition to dltA, other genes in this operon 
(lmo0973 (dltB) and lmo0971 (dltD)) were also significantly upregulated as a result of 
treatment of sigmastatin. Therefore, it is possible that dltB and dltD are also σB 
dependent, yet have not been discovered as such because of less consistent negative 
regulation.   
Noticeably more σB-dependent genes were inhibited by sigmastatin than were 
induced, therefore, σB-dependent genes from multiple conditions previously tested 
(35, 45, 72, 77, 98) were compared to identify trends in σB regulation.  Only a very 
small core group of σB negatively regulated genes (14 of 264 total) were recurrent in 
multiple assays (i.e. genes that were identified as negatively regulated by σB in two or 
more assessments of σB dependence). Conversely, there was a large core group of σB 
positively regulated genes (137 of 282) (i.e. genes that were identified as positively 
regulated by σB in two or more assessments of σB dependence) (Table 4.5). Therefore, 
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it seems that the accuracy of predicting a “regulon” of σB repressed genes based on 
one assay condition is lower than for positively regulated genes, as seen by increased 
variability among σB repressed genes from different assays. This variability is likely a 
consequence of the differences introduced at each level of regulation by other 
transcription factors that overlap in regulation of so-called σB-repressed genes (Table 
4.5). It is evident however, that sigmastatin truly targets the core σB regulon, as it 
inhibited transcription of 125 of the 137 genes that were positively regulated by σB in 
two or more assays. 
 
Sigmastatin reduces L. monocytogenes invasion of human enterocytes 
To quantify the effect of sigmastatin on L. monocytogenes invasion in Caco-2 
human enterocytes, the invasion capacity of exponential phase L. monocytogenes cells 
was assessed after exposure to a low concentration of NaCl (0.3M) known to induce  
σB-activity and treatment with or without sigmastatin. Treatment with sigmastatin, at 
both 64µM and 8µM, significantly reduced L. monocytogenes invasion capacity by 
approximately 1.4 and 1.5 logs, respectively, producing a 25 and 32 fold reduction in 
invasion capacity as compared to WT invasion (Figure 4.6; p<0.05). ]This provides 
clear phenotypic evidence that sigmastatin hinders virulence functions regulated by 
σB, which are critical to the establishment of orally acquired listeriosis (30). 
 
Inhibition of σB in B. subtilis indicates specificity across genera 
In order to determine if sigmastatin could inhibit σB activity in the closely 
related Gram-positive microbe B. subtilis, a β-galactosidase enzymatic assay 
monitoring a σB-dependent ctc-lacZ reporter fusion in B. subtilis was utilized. This 
assay showed that treatment with sigmastatin at 64µM significantly inhibited σB- 
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Figure 4.6: Invasion assay. Bar graph of invasion efficiency of L. monocytogenes in 
the human intestinal epithelial cell line Caco-2. Strains and corresponding treatments 
are indicated on the x-axis. These include wildtype treated with 0.3M NaCl (wt salt), 
wildtype treated with 0.3M NaCl & 64µM sigmastatin (wt salt & 64µM sigmastatin), 
wildtype treated with 0.3M NaCl & 8µM sigmastatin (wt salt & 8µM sigmastatin), 
and the isogenic sigB null strain treated with 0.3M NaCl (∆sigB salt). Invasion 
efficiency was calculated as the number of bacteria recovered relative to the number of 
bacteria used for inoculation (i.e., Log ([CFU/ml recovered] /[CFU/ml inoculated]). 
Data represent four biological replicates, each performed in triplicate. Bars with 
different letters indicate strain/treatments that differed significantly (p<0.05; GLM 
Tukey). These experiments demonstrate the utility of the identified compound at 
inhibiting attachment and invasion of human enterocytes. 
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Figure 4.7: B. subtilis β-galactosidase assay. Bar graph of β-galactosidase activity in 
Miller Units (MU) from B. subtilis strains with (a) σB-dependent Pctc-lacZ reporter 
fusions exposed to various conditions. These include wildtype treated with 0.3M NaCl 
and DMSO (wt salt), wildtype treated with 0.3M NaCl & 64µM sigmastatin (wt salt & 
64µM sigmastatin), wildtype treated with 0.3M NaCl & 8µM sigmastatin (wt salt & 
8µM sigmastatin), and the isogenic sigB null strain treated with 0.3M NaCl (∆sigB 
salt) and DMSO. (b) shows σA-dependent PrsbRSTU-lacZ fusion treated with either 
0.3M NaCl & 64uM sigmastatin (PsigA-lacZ salt & 64µM sigmastatin) or 0.3M NaCl 
& DMSO (PsigA-lacZ salt & DMSO).  Data represent at least three biological 
replicates. Bars with different letters indicate strain/treatments that differed 
significantly (p<0.05; GLM Tukey). Sigmastatin (64µM) inhibits σB activity in B. 
subtilis, producing lacZ levels similar to those in a B. subtilis ∆sigB strain. Some 
inhibition also occurs at 8µM concentration of sigmastatin. Sigmastatin treatment does 
not affect σA activity. This data shows the identification identified an effective and 
specific inhibitor of σB-dependent gene expression, which is effective in different 
Gram-positive bacteria (i.e., the genera Listeria and Bacillus). 
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dependent ctc lacZ enzyme activity (p<0.05; GLM Tukey) almost 2 fold, to levels 
equivalent to a ∆sigB strain (Figure 4.7a ; p>0.05). Treatment with 8µM sigmastatin 
also reduced σB-dependent enzyme activity, however, not significantly from WT salt 
treated cells (p>0.05; GLM Tukey). Notably, a σA-dependent lacZ fusion (104) 
showed no difference in β-galactosidase activity when treated with 64µM sigmastatin 
or DMSO (Figure 4.7 b), further pointing to the specificity of sigmastatin for 
inhibiting σB. 
 
DISCUSSION 
Using a high-throughput screen of 57,000 small molecules, 41 candidate 
compounds were identified as potential inhibitors of the L. monocytogenes σB 
alternative sigma factor; subsequent screens produced one compound that specifically 
interfered with σB activity. Sigmastatin selectively inhibited σB-mediated transcription 
as shown by qRT-PCR of σB-dependent genes and whole-genome microarray analysis 
of cells treated with the compound relative to untreated cells. This compound also 
prevented L. monocytogenes invasion into human intestinal epithelial cells and 
inhibited σB-directed activity in the Gram-positive bacterium B. subtilis. Overall our 
data show (i) novel small molecules can inhibit the σB regulon with high specificity 
and yield transcriptional profiles similar to a genetic null mutation of the sigB gene 
and (ii) one such compound can be used to prevent expression of L. monocytogenes 
virulence factors important to disease etiology, also inhibiting σB activity across 
genera.  Thus, these results provide further evidence that chemical genetics is a 
valuable approach for identifying potential novel anti-infective therapeutics via 
targeting transcription factors.  
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The identified small molecule inhibits σB regulon with high specificity and yields 
transcriptional profiles similar to a genetic null mutation.  
A conserved protein is a valuable target against which novel anti-infectives can 
be developed because of their potential to provide broad-spectrum anti-virulence 
drugs. In fact, screens have identified a class of inhibitors effective against the 
conserved type 3 secretion system (TTS) in pathogens Yersinia spp., Salmonella spp., 
Shigella flexneri, P. aeruginosa, Escherichia coli, and Chlamydia spp. (3, 39, 44, 66, 
68, 69, 105).  Similarly, from a collection of 150,000 compounds, a highly effective 
inhibitor of the virulence-associated membrane histidine sensor kinase QseC in 
enterohemorrhagic E. coli (78) was also found to inhibit QseC homologs in other 
pathogens (i.e., S. Typhimurium, Francisella tularensis). In addition, Lieberman et al. 
used a small molecule screen to identify neuroleptic drugs that have potential as 
therapeutics for various intracellular bacterial pathogens, including L. monocytogenes 
(55, 56). These studies indicate that compounds identified as interfering with 
virulence-associated characteristics in one pathogen may be effective in a broad range 
of bacterial pathogens.  
Limited work, however, has been performed to identify novel inhibitors of 
transcription factors for therapeutic use.  In a eukaryotic system, Koehler et al., 2003 
(52) used a small molecule microarray and transcriptional profiling to identify a small-
molecule inhibitor of the Hap3p subunit of Hap 2/3/4/5p yeast transcription factor, 
whose regulation of mitochondrial function is relevant as a model system for 
identifying inhibitors of human diseases such as diabetes and cancer. The identified 
compound produced a transcriptional profile equivalent to a chemical genetic 
knockdown of Hap2/3/4/5p.  In prokaryotes, there have been some successes in 
identifying small molecules that inhibit members of the AraC family of transcriptional 
regulators. This family of regulators, like σB, contributes to the transcription of 
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multiple stress response (54) and virulence factors (6, 27), providing a target whose 
activity is broad in scope, rather than a target whose discrete virulence-associated gene 
product is unique to a single organism (9). In fact, Hung et al. identified a small 
molecule inhibitor of V. cholerae virulence transcriptional regulator ToxT (an 
AraC/XylS transcriptional regulator) that inhibited the transcription of critical 
virulence components: cholera toxin and toxin co-regulated pilus (40).  Small 
molecules have also been used to target other proteins from the AraC family of 
bacterial transcription factors, including MAR proteins MarA, SoxS and Rob in E. coli 
(9) and LcrF in Yersinia spp (49), preventing regulator-DNA binding. These 
compounds were successful at inhibiting virulence in vitro and in vivo, suggesting that 
targeting a pathogen at the transcriptional level is very effective method for inhibition. 
Another screen identified compounds that inhibit binding of β1 of core RNAP to σ70 in 
E. coli (31). To our knowledge, ours is the first evidence for the identification of a 
small-molecule inhibitor of a bacterial alternative sigma factor that targets a large 
majority of its regulon, producing a transcription profile similar to that of a sigma 
factor null strain thus mimicking the loss of functional σB in a cell. 
The small molecule identified here, sigmastatin, targets σB at an IC50 of 3.5uM. 
The observed activity levels in this low micromolar range are promising because the 
minimal bacteriocidal concentrations of gentamycin, ampicillin, and streptomycin 
(against L. monocytogenes) are in the range of 2 - 46 µM (63) and the ToxT-inhibiting 
virstatin (40) showed an MIC between 3 and 40 µM (depending on the target strain). 
According to whole-genome microarray analysis, 64µM sigmastatin treatment 
produced inhibition of 55% (156/282) of all genes shown to be positively regulated by 
σB under at least one condition (of 7 assessed) and inhibition of >91% (125/137) of 
genes positively regulated by σB under two or more assay conditions (35, 45, 71, 72, 
77, 98).   Observation of multiple assays indicates that while 264 genes were shown to 
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be repressed by σB under at least one condition in multiple assays (35, 45, 72, 77, 98), 
only 14 were differentially expressed under two or more conditions. Interestingly, 
sigmatatin upregulated only 7 of these 264 σB repressed genes, none of which are 
among the 14 σB-dependent genes identified under two or more conditions, suggesting 
limited utility in targeting negatively regulated genes. The results of treatment with 
this compound may highlight the more central role of σB as a positive regulator with a 
strong core of positively regulated genes and an indirect role as a negative regulator 
with very limited set of genes directed under multiple conditions.  
Toledo-Arana et al. (98) identified 172 genes in L. monocytogenes EGDe, 
which were up regulated by σB in the mouse intestinal lumen.  Sigmastatin 
significantly downregulated 126 of these genes and significantly upregulated 1 of 
these genes. Of these genes, 17 were σB-dependent specifically in the intestinal 
infection (98).  Not only is σB is critical to L. monocytogenes adaptation and virulence 
in the intestine (98) and throughout the gastrointestinal tract in its entirety (29), but it 
also regulates genes involved in intracellular survival and proliferation (16). The 
effectiveness of this compound at producing a σB null status in the cell, inhibiting 
genes which are important during intestinal infection and preparation for systemic 
infection as well as adaptation for the intracellular environment, strongly suggests that 
this compound holds promise as an excellent therapeutic or prophylactic for the 
treatment of listeriosis.   
 
Small molecules targeting σB can be used to probe stress response and regulatory 
networks in L. monocytogenes  
To also ascertain whether sigmastatin activity was specific to σB, the effect of 
our anti-infective compound on other alternative sigma factors, including σH and σL, 
was assessed. σH is important to growth in minimal and alkaline media (80) and 
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previous microarray analysis showed that much of the σH regulon overlaps with that of 
σB. Therefore, the effect of sigmastatin on the σH regulon was evaluated.  It was 
determined that the majority of the σH-regulated genes that were affected by the 
compound were also regulated by σB and that the σH-only regulon (the set of genes in 
which σB co-regulated genes were removed) was not enriched. σL, also known as 
RpoN, contributes to carbohydrate metabolism and antimicrobial resistance (2, 81) 
and is associated with σB in so doing (74). The σL regulon, however, was not enriched 
in our microarray dataset.  Moreover, this compound exhibited specificity for this 
alternative sigma factor in that it not only inhibited L. monocytogenes σB, but it also 
inhibited σB activity (but had no effect on σA activity) in the Gram-positive model 
organism B. subtilis, which is closely related to other low G+C content pathogens. 
These assessments support the notion that σB is a preferential alternative sigma factor 
target. 
Multiple lines of evidence demonstrate a central network between σB and PrfA 
(14, 72), which coordinates in vivo expression of genes required for the infectious 
process (14). The direct regulatory control σB has over PrfA via the P2prfA promoter is 
well established (67, 79, 85), however, it is increasingly clear that there are additional 
layers of indirect σB regulation. As suggested by Ollinger et al., σB may act as a 
posttranscriptional switch that downregulates excessive PrfA activity (72). Those data 
indicated that multiple virulence genes were differentially expressed in the presence of 
PrfA* depending on the presence or absence of σB. Specifically, σB moderated the 
PrfA regulon in a PrfA* background helping to mediate host-cell damages effects of 
PrfA-dependent virulence genes (72). In our dataset, the PrfA regulon was 
significantly enriched among sigmastatin-downregulated genes. The fact that two 
PrfA-dependent genes, lmo0937 and plcA, with no known association with σB 
regulation, were both downregulated by an otherwise σB-specific inhibitor 
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(sigmastatin), suggests there are additional and complex layers of regulation and fine 
tuning that occur between PrfA and σB.  However, it is evident that the interplay 
between these regulators is fundamental in order to co-regulate these subsets of 
virulence genes to survive and promote infection.  
Mounting evidence points to a fundamental role for σB in chemotaxis and 
motility. Specifically, several genes in a large operon of flagellar structural 
components were identified to be negatively regulated by σB (77). Additionally, sigB 
null mutants exhibit increased swarming on agar (77, 98). We surmise that the 
complex relationship of σB to motility could be explained by direct or indirect co-
regulation with one or more of the multiple regulators (DegU, MogR and CodY) 
involved in motility and chemotaxis, allowing for fine-tuning of L. monocytogenes 
response to varied environments.  As a result of sigmastatin treatment, several genes 
important to motility and chemotaxis were upregulated.  Specifically, 6 genes on the 
flagellum biosynthesis operon (lmo0673-0718) were significantly and differentially 
upregulated. Although they were not among the 13 previously identified σB-dependent 
genes found in this operon (77), they were interspersed among them on the operon.  
The majority of this flagellar operon is regulated by DegU, a positive activator of 
flagellum biosynthesis (51), including those 6 sigmastatin upregulated genes (103).  
Furthermore, 2 genes upregulated by sigmastatin, which comprise the methyl-
accepting chemotaxis operon, lmo1699 and lmo1700, are negatively regulated by σB 
(77) and are also regulated by DegU (103).  In fact, the DegU and CodY regulons, but 
not MogR, were significantly enriched among upregulated genes, suggesting an 
overlap with the negative regulatory function that σB has on motility (77, 98). 
Furthermore, while Listeria is known to downregulate flagellar genes during infection 
(14) to evade the immune system, increased expression of flagellar components can 
induce potent proinflammatory affects via TLR5-mediated immunogenicity (100). 
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Therefore, the ability of sigmastatin to upregulate flagellar components validates its 
potential as an anti-listeriosis drug.  
These data regarding the expression of various regulons after treatment with a 
target-specific compound, such as sigmastatin, support the assertion of complex 
networks among transcription factors in L. monocytogenes (18, 38). 
 
Small molecules targeting transcriptional regulators, including alternative sigma 
factors, show promise as therapeutic and environmental control agents 
Chemical genetics entails the use of small molecules to probe and/or alter 
biological targets, allowing for a better understanding of certain processes and for 
identification of novel therapeutics.  Identifying compounds that are active against 
biological targets such as disease-causing mechanisms of pathogenesis in 
microorganisms has proven to be successful approach for developing new classes of 
“antibiotics”.  Specifically, previous work using high-throughput screens to identify 
small-molecule inhibitors of virulence in V. cholerae were successful, allowing for the 
identification of the small molecule that disrupted protein-protein interactions of 
transcription factor ToxT, resulting in the prevention and treatment of cholera post-
infection.  In the high-throughput assay, we found that of the genes inhibited by 
sigmastatin, 75% were previously reported as σB
The alternative sigma factor σ
 dependent (35, 45, 72, 77, 98).  This 
shows genome wide evidence for inhibition by a highly selective small molecule 
capable of modulating transcriptional regulation of genes critical to stress response 
and virulence in the Gram-positive pathogen L. monocytogenes. 
B is important for responding to stimuli from 
specific environments including those triggered by transit through the host 
gastrointestinal tract (4, 29). σB modulates gene expression, including expression of 
stress response and virulence factors, and is therefore important to establishing an 
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infection in the mammalian host.  In addition to σB’s role in transcription of virulence 
and in vivo viability associated genes, there is burgeoning evidence that σB contributes 
to infection in animal models. In B. anthracis, Fouet et al. (28), showed that a deletion 
mutant of sigB was less virulent than the isogenic parental strain. Specifically, there 
was a one log-unit lower LD50 in a B. anthracis sigB mutant as compared to the parent 
strain. The authors suggest that sigB may contribute to virulence by allowing B. 
anthracis to persist in the bloodstream of the mammalian host during septicemia, the 
final stage of anthrax (28).  In Staphylococcus aureus, σB controls a sarA promoter 
and SarA activates agr, which in turn encodes a protein that regulates virulence.  
According to Jonsson et al (42), a S. aureus strain, which was defective in σB activity 
because of an impaired posttranslational activator of σB (rsbU), showed increased 
arthritogenicity and sepsis compared to a strain with a repaired rsbU.  Similar to B. 
anthracis, Jonsson et al. suggested that either σB itself or regulation of it by RsbU 
promotes S. aureus survival in the bloodstream, preventing clearance and allowing 
establishment of infection (42). Furthermore, Lorenz et al. also showed that functional 
loss of σB results in a decrease of S. aureus virulence in central venous catheter-related 
diseases manifested by significantly reduced multiorgan infection caused by σB 
deficient strains (59). In L. monocytogenes, Garner et al. showed that as compared to a 
wildtype strain, a sigB null strain of L. monocytogenes shows reduced infection in a 
guinea pig model via an intragastric route (30). Because of its role in virulence and 
viability of multiple human pathogens in the host, σB
In our phenotypic and transcriptional profiling experiments, σB-dependent 
virulence genes, such as inlAB, bsh, bilE, clpC and hfq were significantly 
downregulated as a result of treatment with sigmastatin. While each of these genes has 
been shown to contribute to virulence individually (14, 19, 23, 57, 82, 91), a 
 represents a suitable target for 
inhibition by novel small molecules.  
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compound that can inhibit transcription of all of these genes provides an increased 
advantage over a compound that targets only one virulence factor (9). Furthermore, 
stress response and virulence-associated genes opuC (92) and gadA (20), which are 
important to survival during passage through the host, were also significantly 
downregulated by the compound.  The ability of this compound to target a wide array 
of genes required for virulence and in vivo viability suggests it has great promise as a 
therapeutic, as the targeted genes directly contribute to pathogenesis in an animal 
model. 
The Caco-2 human intestinal epithelial cell line provides insight into the 
interaction between the intracellular pathogen L. monocytogenes and intestinal 
epithelial cells and correlates well to the animal model (30).  σB is essential for 
attachment and infection of enterocytes, as demonstrated in Caco-2 human intestinal 
epithelial cells (30, 48) and is also a requirement for invasion and establishment of 
infection in the guinea pig model of listeriosis.  We used this in vitro system to 
determine the effect sigmastatin has on the ability of L. monocytogenes to invade 
human enterocytes. Sigmastatin severely impedes L. monocytogenes attachment and 
invasion of human intestinal epithelial cells, likely because of the drastically reduced 
expression of σB-directed virulence genes inlA and inlB. In fact, sigmastatin inhibited 
σB activity to such a degree that it reduced L. monocytogenes invasion capacity to that 
of a ∆sigB strain.  Most notably, sigmastatin worked rapidly; affecting σB directed 
transcription in less than 10 minutes and subsequent translation in less than 30 minutes 
of treatment (according to qRT-PCR and invasion assays). This model provides strong 
phenotypic substantiation that this inhibitory small molecule is able to hinder the 
virulence functions of σB, which are critical to the establishment of orally acquired 
listeriosis. 
Emerging evidence supports that transcription factors in microorganisms are 
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also promising targets for anti-virulence inhibitors (9, 40, 49, 87). These conserved 
proteins control multiple genes important to virulence, regulating mechanisms of 
pathogenesis across multiple microorganisms. This work demonstrates that the 
regulator critical for L. monocytogenes gene expression during infection and stress 
survival is an excellent target for broad range novel therapeutics. Indeed, from our 
screen of 57,000 compounds we found that sigmastatin inhibition was specific across 
genera, substantiating the assertion that such a compound can be used to target 
homologues of this protein regulator in Gram-positive pathogens.  This type of 
chemical modulator of virulence and in vivo viability, which impairs bacterial invasion 
and persistence in the host via inhibition of genes also increases the microbe’s 
susceptibility to mammalian host defenses. Such a compound can render the organism 
innocuous and easily cleared by the immune system. This is particularly beneficial for 
immunocompromised hosts, for whom listeriosis causes the highest morbidity and 
mortality (25-45%) (32).   
Targeting an alternative sigma factor for the development of anti-virulence 
therapeutics may be beneficial for other diseases for which emerging drug-resistance 
is thwarting treatment.  In fact, this approach might also be applied to alternative 
sigma factor σF (closely related to σB) (25, 73) in Mycobacterium tuberculosis, which 
regulates virulence-associated genes important to pathogenesis (90, 93) and 
antimicrobial resistance (62). This work also establishes a foundation for developing 
small molecules that can be used to interfere with the ability to survive environmental 
stress conditions, proving beneficial for controlling transmission and reservoirs of 
pathogens that persist in the environment. For example, because certain families of 
alternative sigma factors are conserved, it is possible to use an inhibitor similar to the 
one discovered in this work, to control sporeformers. Not only are σB and σF important 
for many Gram-positive pathogens’ survival in the host, they are also important for 
             124
  
enabling survival outside the host prior to infection (99). In fact, a sigB deletion strain 
of B. cereus, a foodborne pathogen and close relative of B. anthracis, exhibits delayed 
onset of sporulation and subsequently, less efficient germination (99). Furthermore, 
development of compounds targeting σF
By utilizing chemical-genetics strategies, identification of anti-virulence agents 
active against L. monocytogenes transcriptional regulators, such as alternative sigma 
factors, could produce human chemotherapeutics active against a number of similar 
Gram-positive pathogens.  Such strategies would potentially help avoid the misuse of 
classical antibiotics, preserving their efficacy for situations warranting their 
application.  This approach affords us the opportunity to develop novel agents which 
abrogate or reduce L. monocytogenes pathogenicity and possibly other Gram-positive 
clinically relevant pathogens, which will help to mitigate the burdens currently 
beleaguering public health and safety. This research provides a better understanding of 
the benefits derived from employing chemical genetics in concert with microbiology 
for drug development for human pathogens. By extrapolating what we learn from one 
organism and harnessing this knowledge, we can rationally develop drugs intended to 
target the very factors which are essential to microbial survival in the host and 
pathogenicity in a number of similar disease-causing microorganisms. 
, which is important to sporulation in B. 
anthracis (24), may provide a form of environmental control of anthrax. The 
application of a compound that produces a more susceptible cell is ideal for sensitizing 
the cell to control agents and other preventative measures. As our data demonstrates, 
targeting alternative sigma factors is a worthwhile approach to consider for future drug 
development or environmental control agents for inhibition of microbial transmission.  
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 CHAPTER 5 
CONCLUSIONS 
 
Listeria monocytogenes has the highest fatality rate among foodborne pathogens and 
disproportionately affects infants, the elderly and immunocompromised individuals. 
The loss of life and financial burdens caused by L. monocytogenes warrant 
investigation into new methods for control and alleviation of this public health threat. 
Increasing interest in employing chemical genetics to answer questions in the realms 
of both eukaryotic and prokaryotic biology has permitted a better understanding of 
biological functioning (e.g. pathways and proteins) (12). Chemical genetics has also 
lent itself to the identification of valuable compounds with potential for treating 
human diseases, such as those caused by harmful viruses, parasites, and bacteria (4-6, 
8, 11). In particular, this approach has been successfully used to inhibit transcription 
factors from the AraC family of regulators which contribute to virulence in several 
bacterial pathogens (1, 2).  
Building upon this foundation, we set out to identify new bacterial targets in L. 
monocytogenes for anti-infective development.  First, our research aimed to determine 
the contributions of select transcriptional regulators to virulence and to antimicrobial 
resistance to select peptides. Results from the research supported that σB promotes 
invasion, PrfA is critical to cell-to-cell growth and showed that CtsR, in addition to 
PrfA and σB, are important to virulence in a guinea pig model of listeriosis. Moreover, 
σB and σL both contribute to antimicrobial peptide resistance, coordinating response to 
both SdpC and nisin. Therefore, we chose the alternative sigma factor σB as our target 
of choice for anti-infective development because of its role in regulating stress 
response and antimicrobial resistance, promoting in vivo viability and contributing to 
virulence in L. monocytogenes. In order to discover novel small molecules capable of 
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attenuating human listeriosis via inhibition of σB, we used a high-throughput format to 
screen ~57,000 small molecules to identify selective inhibitors of σB.  The resulting 
promising compounds were reassessed using a secondary cell-based HTS format as 
well as qRT-PCR; one select compound was then comprehensively validated through 
a variety of methods such as transcriptional profiling, phenotypic assessments, and 
mammalian tissue culture infection models.  We identified a potential anti-virulence 
agent, sigmastatin, with high specificity for σB in both Listeria and Bacillus, producing 
a chemically induced σB null status equivalent to a genetic knockout of σB in the cell.  
This novel agent inhibited invasion thus reducing L. monocytogenes pathogenicity 
pointing to the possibility of application against other Gram-positive clinically 
relevant pathogens.  
We anticipate that this work will further the development of novel therapeutic 
agents that are detrimental to the pathogenic potential of prokaryotes but entirely 
benign to eukaryotes. In using the approach described in the work presented here, the 
ultimate goal is to help reduce public health and safety issues caused by the foodborne 
pathogen L. monocytogenes, while avoiding the misuse of classical antibiotics and 
preserving them for warranted situations. For the future of this work, the next steps to 
pursue would involve forming a complete picture of sigmastatin’s mode of action. In 
order to do this: (i) numerous derivatives of this compound will need to be tested in 
order to determine the most important sub-structures on the molecule that contribute to 
optimal inhibition and (ii) sigmastatin target-identification will need to be performed. 
As data from our small-molecule microarray suggested the possibility that σB and 
sigmastatin bind, we hope to elucidate how sigmastatin is inhibiting σB activity via 
identification of true targets. Previous work has shown that small molecules can 
inhibit protein-protein interactions (9) or protein-DNA interactions (3), thus, we 
surmise that sigmastatin may act in a number of ways. For instance, it may prevent 
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effective core RNAP- σB association and/or subsequent promoter binding or it may act 
upstream on regulators of σB (Rsb). We suggest using a general target identification 
method such as SILAC (stable isotope labeling with amino acids in cell culture) (7) or 
a more specific method such as SPR (surface plasmon resonance). SILAC, which is 
used in quantitative proteomics, involves a combination of isotope labeling, affinity 
chromatography and mass spectrometry to identify any potential protein binders to a 
bead-conjugated small molecule (SM). This method entails the use of one lysate 
population labeled with a light isotope and exposed to both a bead-affixed SM and a 
soluble SM (that acts as competitor bait reducing the number of target proteins that 
bind the SM-bead) and one lysate population labeled with heavy isotope exposed only 
to the SM-bead. The resulting heavy to light peptide fragment ratio allows for 
identification of true protein “interactors” using mass spectrometry (7). We might also 
use SPR to immobilize a variety of potential targets to determine affinity and 
specificity of protein-ligands pairs or even to determine the effects of a small molecule 
ligand on a protein complexed with other molecules, such as DNA. Alternatively, a 
genetic approach can be used to identify the protein target of sigmastatin. This would 
involve screening for bacteria exhibiting a resistance phenotype, such as mutant 
colonies able to deconjugate bile salts on selective agar containing inhibitory levels of 
sigmastatin. Subsequently, the mutant colonies would be assessed to determine a 
genetic explanation for resistance using total genome sequencing approaches, such as 
Solexa (Illumina) or 454 sequencing, pinpointing mutations in the target that elicited 
resistance (10). Ultimately, this information may allow for the realization of a highly 
effective listeriosis treatment option. 
Identification of sigmastatin and a subsequent understanding of its mode of 
action serve as a stepping stone for the identification of similar compounds targeted 
against other sigma factors of interest. We anticipate that this may provide an avenue 
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for the generation of compounds aimed at an expansive array of applications (beyond 
anti-virulence agents), such as the identification of environmental control agents or 
simply for improving our current understanding of gene regulation and regulatory 
networks. 
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Appendix Table AT.1: Secondary Screening candidates 
Virtual ID Vender ID Decision 
Result of σB 
inhibition 
SPBio_000086 Spectrum01500167 Not available commercially 
Possible growth 
inhibitor 
SPBio_000596 Spectrum00210477 
Effective in secondary, Not available 
commercially at the time, actinonin Might work 
SPBio_001858 Spectrum00200034 
Effective in secondary, Not available 
commercially at the time, atranorin Might work 
SPBio_002673 Prestwick_000747 Not pursued after secondary, antibiotic 
Possible growth 
inhibitor 
Ald1.1-H_000308  Would need resynthesis Might work 
ACon1_001486 NP-005144 Not available 
Possible growth 
inhibitor 
ChemDiv3_002815 4151-0291 Not pursued after secondary 
Possible growth 
inhibitor 
ChemDiv3_002999 4237-0075a Pursued after secondary Not effective 
ChemDiv3_005866 6145-0438 Not pursued after secondary 
Possible growth 
inhibitor 
ChemDiv3_005911 6079-1959 Not pursued after secondary Unclear 
ChemDiv3_006137 6228-2502 
Not pursued after secondary, aryl 
hydrazone Might work 
ChemDiv3_007160 8012-2663 Not pursued after secondary Unclear 
ChemDiv3_007374 8009-2163 a 
Pursued after secondary, minimal 
cytotoxicity 
Works-used 
derivative T0513 
ChemDiv3_010387 C614-5726 
Not pursued after secondary, aryl 
hydrazone Might work 
ChemDiv3_010413 C660-0131 Not pursued after secondary, cytotoxic Might work 
Maybridge4_001879 JFD00174 Not pursued after secondary Unclear 
Maybridge4_001886 JFD02846 Not pursued after secondary Unclear 
Maybridge4_001932 JFD03061 a Pursued after secondary 
Works- needs 
optimization 
Maybridge4_001966 JFD02331 Not pursued after secondary 
Possible growth 
inhibitor 
Maybridge4_001967 JFD00263 Not pursued after secondary 
Possible growth 
inhibitor 
Maybridge4_002150 KM06170 
Not pursued after secondary, aryl 
hydrazone Might work 
Maybridge4_002415 KM04727 
Not pursued after secondary, aryl 
hydrazone Might work 
Maybridge4_003857 S13598 
Pursued as growth inhibitor, not 
effective as sigB or growth inhibitor Not effective 
Maybridge4_004192 SEW02081 Not pursued after secondary Might work 
Maybridge4_004329 SP01461 Not pursued after secondary 
Possible growth 
inhibitor 
Maybridge4_004330 SPB02585 Not pursued after secondary Might work 
Maybridge4_004364 SPB01534 Not pursued after secondary Might work 
Maybridge4_004503 SP01411 Not pursued after secondary Unclear 
Maybridge4_004548 SPB02493 
Not pursued after secondary, aryl 
hydrazone Might work 
Maybridge4_004591 SPB06794 Not pursued after secondary Might work 
Maybridge4_004694 SPB06723 
Not pursued after secondary, aryl 
hydrazone Might work 
Enamine_001246 T0504-0705 
Not pursued after secondary, problems 
with dilution Unclear 
Enamine_001250 T0500-0388 
Not pursued after secondary, problems 
with dilution Unclear 
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Enamine_001604 T0505-1745 
Not pursued after secondary, aryl 
hydrazone, problems with dilution, 
structure similar to 4237-0075  Unclear 
TimTec1_003523 ST047887 Not pursued after secondary 
Possible growth 
inhibitor 
TimTec1_003545 ST050178 Not pursued after secondary, cytotoxic Might work-ytotoxic 
TimTec1_003817 ST050863 Not pursued after secondary 
Possible growth 
inhibitor 
TimTec1_003987 ST057360 Not pursued after secondary Unclear 
TimTec1_005049 ST212074 Not pursued after secondary Might work 
TimTec1_005093 ST211458 Not pursued after secondary Unclear 
TimTec1_007542 ST5024987 Not pursued after secondary Unclear 
a Compounds or derivatives of compounds in bold were assessed further using qRT-PCR, etc. 
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Appendix Figure AF.1: Scatterplot of small-molecule microarray screen. Three-
dimensional scatterplot of Z-scores calculated from normalized fluorescence intensity 
resulting from interaction between σB and printed small-molecule ligands. Arrays were 
tested in triplicate and bound His-tagged σB was detected using Alexa Fluor 647 
labeled anti-His antibody. Red dots represent DMSO controls; blue dots are small 
molecules ligands tested. 
control spot 
compound spot 
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